SLC17A8-related autosomal dominant nonsyndromic hearing loss is usually progressive and predominantly high-frequency, with variable onset and age-dependent penetrance. VGLUT3 loads glutamate into inner hair cell synaptic vesicles. Human segregation establishes the gene-disease relationship, but the dominant molecular mechanism remains unresolved. Homozygous null mice lack sound-evoked afferent signaling; homozygous A224V knock-in mice, modeling human A211V, develop inner hair cell bundle disruption followed by ribbon and exocytosis changes. Heterozygous knock-in mice have a much milder phenotype. These models establish complementary experimental findings rather than interchangeable accounts of human disease. The limited human otoacoustic-emission data do not settle whether DFNA25 belongs within the auditory neuropathy spectrum.
Ask a research question about Autosomal Dominant Nonsyndromic Hearing Loss 25. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Autosomal Dominant Nonsyndromic Hearing Loss 25:
name: Autosomal Dominant Nonsyndromic Hearing Loss 25
creation_date: "2026-09-01T20:30:00Z"
category: Mendelian
disease_term:
preferred_term: autosomal dominant nonsyndromic hearing loss 25
term:
id: MONDO:0011568
label: autosomal dominant nonsyndromic hearing loss 25
synonyms:
- DFNA25
- deafness, autosomal dominant 25
- autosomal dominant nonsyndromic deafness 25
- SLC17A8 autosomal dominant nonsyndromic deafness
- autosomal dominant nonsyndromic deafness caused by mutation in SLC17A8
description: >-
SLC17A8-related autosomal dominant nonsyndromic hearing loss is usually progressive and predominantly
high-frequency, with variable onset and age-dependent penetrance. VGLUT3 loads glutamate into inner
hair cell synaptic vesicles. Human segregation establishes the gene-disease relationship, but the dominant
molecular mechanism remains unresolved. Homozygous null mice lack sound-evoked afferent signaling; homozygous
A224V knock-in mice, modeling human A211V, develop inner hair cell bundle disruption followed by ribbon
and exocytosis changes. Heterozygous knock-in mice have a much milder phenotype. These models establish
complementary experimental findings rather than interchangeable accounts of human disease. The limited
human otoacoustic-emission data do not settle whether DFNA25 belongs within the auditory neuropathy
spectrum.
parents:
- Autosomal Dominant Nonsyndromic Hearing Loss
- Hereditary Hearing Loss
external_assertions:
- name: ClinGen SLC17A8-nonsyndromic hearing loss gene-disease validity assertion
source: ClinGen
assertion_type: gene_disease_validity
external_id: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
description: >-
The ClinGen Hearing Loss Gene Curation Expert Panel raised the SLC17A8-autosomal dominant nonsyndromic
hearing loss relationship from Strong in 2018 to Definitive in June 2023. Its assessment included
at least eight variants in nine probands and segregation in 28 additional relatives. These are counts
in that dated evidence assessment, not worldwide case totals or prevalence estimates.
evidence:
- reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
reference_title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
supports: SUPPORT
evidence_source: OTHER
snippet: "SLC17A8 | HGNC:20151 | nonsyndromic genetic hearing loss | MONDO:0019497 | AD | Definitive"
explanation: >-
The expert-panel classification row itself, with gene, disease, inheritance mode and
verdict.
- reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
reference_title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
supports: SUPPORT
evidence_source: OTHER
snippet: >-
At least 8 unique variants (missense, frameshift, splice site) have been reported in
humans in 9 probands
explanation: >-
Counts in the June 2023 ClinGen assessment, not current worldwide totals or a prevalence denominator.
- reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
reference_title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
supports: SUPPORT
evidence_source: OTHER
snippet: >-
As a result of this reevaluation, the classification increased from Strong to
Definitive due to additional case level evidence
explanation: >-
The expert panel upgraded the relationship from Strong to Definitive in 2023.
mechanistic_hypotheses:
- hypothesis_group_id: presynaptic_glutamate_loading_failure
hypothesis_label: Presynaptic vesicular glutamate loading failure
status: CANONICAL
description: >-
VGLUT3 deficiency prevents vesicular glutamate loading and auditory afferent activation in homozygous
null mice despite preserved vesicle fusion and cochlear amplification. This is an established null-model
mechanism and a candidate contributor to human SLC17A8 disease. It does not establish haploinsufficiency
or uniform transport loss for dominant variants: A211V retains transport in tested heterologous systems,
and human onset and severity vary.
- hypothesis_group_id: a211v_mechanotransduction_first
hypothesis_label: Stereociliary mechanotransduction failure preceding synaptic change
status: EMERGING
description: >-
Homozygous A224V mice develop inner hair cell stereocilia disruption and reduced summating potentials
before marked ribbon enlargement and increased sustained exocytosis. This supports a mechanotransduction-first
hypothesis in that model. Temporal order does not establish that the bundle lesion causes the synaptic
changes, and the dominant human mechanism remains unconfirmed.
pathophysiology:
- name: Heterozygous SLC17A8 Variant
role: trigger
biological_scale: MOLECULAR
description: >-
The founding c.632C>T (p.A211V) variant segregated in two families with evidence of distant shared
ancestry and was absent from 267 controls. Later reports include c.616dupA (p.M206Nfs*4) and c.763+1G>T.
The 2016 frameshift report sequenced one proband from an affected pedigree; it did not demonstrate
segregation across all eight affected relatives. Predicted truncation and splice disruption do not
establish a shared dominant mechanism.
genetic_context:
gene:
preferred_term: SLC17A8
term:
id: hgnc:20151
label: SLC17A8
variant_origin: GERMLINE
zygosity: HETEROZYGOUS
description: >-
Reported disease-associated alleles are heterozygous. The entry does not assign one functional-impact
category across missense, frameshift and splice variants: human dominance and normal heterozygous-null
mouse hearing do not by themselves distinguish dosage loss, dominant-negative effects or other mechanisms.
downstream:
- target: Altered VGLUT3 Function in the Inner Hair Cell
causal_link_type: DIRECT
description: >-
Every proposed mechanism for this disease runs through the transporter that the
variant sits in.
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In two unrelated families, a heterozygous missense mutation, c.632C-->T (p.A211V), was
found to segregate with DFNA25 deafness and was not present in 267 controls.
explanation: >-
The founding allele, its zygosity, its segregation and its control screening.
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The A211 residue is conserved in VGLUT3 across species and in all human VGLUT subtypes
(VGLUT1-3), suggesting an important functional role.
explanation: >-
The conservation argument the founding paper rests the missense call on.
- reference: PMID:26797701
reference_title: Screening of the SLC17A8 gene as a causative factor for autosomal dominant non-syndromic hearing loss in Koreans.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The novel frameshift mutation, p.M206Nfs*4, in which methionine is changed to
asparagine at amino acid position 206, resulted in a termination codon at amino acid
position 209.
explanation: >-
The 2016 report identified a frameshift in one sequenced proband and predicted truncation; it did
not show cosegregation in all affected relatives.
- reference: PMID:28647561
reference_title: Identification of a novel splicing mutation within SLC17A8 in a Korean family with hearing loss by whole-exome sequencing.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A novel splicing mutation, c.763+1G>T, in the solute carrier family 17, member 8
(SLC17A8) gene was identified in the patients, and the genotypes of the mutation were
co-segregated with the phenotype of HL.
explanation: >-
The splice-donor allele and its co-segregation in a three-generation dominant family.
- name: Altered VGLUT3 Function in the Inner Hair Cell
role: central_effector
biological_scale: MOLECULAR
description: >-
VGLUT3 supports glutamate loading into inner hair cell synaptic vesicles. Null mice lack functional
auditory afferent transmission, but human A211V does not abolish uptake or quantal signaling in tested
heterologous/autaptic preparations. Central-terminal protein reduction in the knock-in cannot be assumed
in cochlear cells: the 2021 study found comparable inner hair cell VGLUT3 immunofluorescence and distribution
between genotypes. Variant-specific effects therefore remain important.
cell_types:
- preferred_term: cochlear inner hair cell
term:
id: CL:0000589
label: cochlear inner hair cell
molecular_functions:
- preferred_term: vesicular L-glutamate transport by VGLUT3
term:
id: GO:0005313
label: L-glutamate transmembrane transporter activity
biological_processes:
- preferred_term: glutamate loading into inner hair cell synaptic vesicles
term:
id: GO:0098700
label: neurotransmitter loading into synaptic vesicle
cellular_components:
- preferred_term: inner hair cell synaptic vesicle
term:
id: GO:0008021
label: synaptic vesicle
downstream:
- target: Impaired Glutamate Release at the Inner Hair Cell Ribbon Synapse
causal_link_type: DIRECT
hypothesis_groups:
- presynaptic_glutamate_loading_failure
description: >-
The direct consequence of an unfilled vesicle, and the route the null mouse takes.
- target: Inner Hair Cell Stereocilia Bundle Disruption
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
hypothesis_groups:
- a211v_mechanotransduction_first
description: >-
The route the allele-matched knock-in mouse takes. It is marked INDIRECT because no
mechanism connecting an altered vesicular transporter to hair-bundle architecture has
been demonstrated; the knock-in shows the bundles collapse, not why.
- target: Synaptic Ribbon Enlargement
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
hypothesis_groups:
- a211v_mechanotransduction_first
description: >-
The A224V genotype is associated with this later synaptic alteration; the intermediates and relationship
to the early bundle defect remain unresolved.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
In addition, IHC ribbon synapses underwent structural and functional modifications at later stages.
explanation: >-
The genotype-associated synaptic findings do not prove that reduced receptor potential caused
them.
quote_role: PRIMARY_RESULT
directness: DIRECT
- target: Increased Sustained Inner Hair Cell Exocytosis
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
hypothesis_groups:
- a211v_mechanotransduction_first
description: >-
The A224V genotype is associated with this later synaptic alteration; the intermediates and relationship
to the early bundle defect remain unresolved.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
patch-clamp membrane capacitance measurements showed an increase in the rate of the sustained
releasable pool exocytosis
explanation: >-
The genotype-associated synaptic findings do not prove that reduced receptor potential caused
them.
quote_role: PRIMARY_RESULT
directness: DIRECT
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
In the cochlea, VGLUT3 accumulates glutamate in the synaptic vesicles of the sensory
inner hair cells (IHCs) before releasing it onto receptors of auditory-nerve terminals.
explanation: >-
The normal function of the protein, which is what the disease removes or alters.
- reference: PMID:26797701
reference_title: Screening of the SLC17A8 gene as a causative factor for autosomal dominant non-syndromic hearing loss in Koreans.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
among its isoforms (VGLUT1-3), only VGLUT3 is expressed selectively in the inner hair
cells (IHCs)
explanation: >-
Inner hair cell expression provides a basis for nonredundant cochlear function. It does not explain
the absence of extra-auditory findings in every carrier.
quote_role: BACKGROUND
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
This variation does not impair the glutamate vesicular accumulation, neither the
quantal release nor the quantal content in hippocampal autaptic neurons
explanation: >-
A negative result at the level of transport itself, which is why this entry does not
assert that the human missense allele simply stops glutamate loading. Graded IN_VITRO
because the measurement is in cultured autaptic neurons.
quote_role: BACKGROUND
directness: INDIRECT
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
the p.A224V variant does not disturb the VGLUT3 targeting within the hair cell cytoplasm.
explanation: >-
Semi-quantitative mouse cochlear immunofluorescence; this limits extrapolation from reduced central-terminal
expression.
quote_role: PRIMARY_RESULT
directness: DIRECT
- name: Impaired Glutamate Release at the Inner Hair Cell Ribbon Synapse
biological_scale: CELLULAR
description: >-
In the Ruel Slc17a8-null line, calcium-triggered vesicle turnover was preserved at two weeks and surviving
ribbons had a normal ultrastructural appearance at three months, while auditory afferent signaling
failed. Other null-model studies reported thin or elongated ribbons. The findings differ by study
and preparation; they do not establish universally normal ribbon morphology or uniform transport loss
in dominant human variants.
cell_types:
- preferred_term: cochlear inner hair cell
term:
id: CL:0000589
label: cochlear inner hair cell
biological_processes:
- preferred_term: glutamate secretion at the inner hair cell afferent synapse
modifier: DECREASED
term:
id: GO:0014047
label: glutamate secretion
downstream:
- target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
causal_link_type: DIRECT
hypothesis_groups:
- presynaptic_glutamate_loading_failure
description: >-
An afferent terminal that receives no transmitter does not fire, however well the
cochlea in front of it is working.
evidence:
- reference: PMID:18215623
reference_title: Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
We now report that mice lacking VGLUT3 are profoundly deaf due to the absence of
glutamate release from hair cells at the first synapse in the auditory pathway.
explanation: >-
The release failure stated directly, and its location at the first auditory synapse.
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Ca(2+)-triggered synaptic-vesicle turnover was normal in IHCs of Slc17a8 null mice when
probed by membrane capacitance measurements at 2 weeks of age.
explanation: >-
The deliberate negative result that localises the defect to vesicle content rather than
to exocytosis. Without it the node would be indistinguishable from a fusion defect.
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
We conclude that deafness in Slc17a8-deficient mice is due to a specific defect of
vesicular glutamate uptake and release and that VGLUT3 is essential for auditory coding
at the IHC synapse.
explanation: >-
The founding paper's own conclusion about the null animal.
- name: Inner Hair Cell Stereocilia Bundle Disruption
biological_scale: CELLULAR
description: >-
Homozygous A224V mice show progressive inner hair cell bundle fusion and collapse with relative preservation
of outer hair cell bundles. VGLUT3 is not localized to stereocilia, and the molecular connection is
unresolved. Protein misfolding/trafficking effects and interaction with the C57BL/6J Cdh23 background
are hypotheses. Comparable inner hair cell immunofluorescence argues against gross protein accumulation
but cannot exclude altered turnover or proteostasis.
cell_types:
- preferred_term: cochlear inner hair cell
term:
id: CL:0000589
label: cochlear inner hair cell
biological_processes:
- preferred_term: inner hair cell stereocilium bundle organization
modifier: DECREASED
term:
id: GO:0060122
label: inner ear receptor cell stereocilium organization
downstream:
- target: Reduced Inner Hair Cell Receptor Potential
causal_link_type: DIRECT
hypothesis_groups:
- a211v_mechanotransduction_first
description: >-
Bundle disruption and reduced summating potential support a mechanotransduction defect in the same
homozygous model; direct mechanotransducer-current impairment was not measured.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Scanning electron microscopy examinations demonstrated the collapse of stereocilia
bundles in IHCs, leaving those from outer hair cells unaffected.
explanation: >-
The bundle finding and its restriction to inner hair cells.
- name: Reduced Inner Hair Cell Receptor Potential
biological_scale: CELLULAR
description: >-
The summating potential is the gross cochlear correlate of the inner hair cell receptor
potential, and it is reduced in the knock-in mouse. Because cochlear amplification is
intact in the same animals, a smaller receptor potential is being generated from a normal
mechanical input - which is what a transduction defect in the inner hair cell looks like
from outside.
cell_types:
- preferred_term: cochlear inner hair cell
term:
id: CL:0000589
label: cochlear inner hair cell
biological_processes:
- preferred_term: mechanotransduction in the inner hair cell hair bundle
modifier: DECREASED
term:
id: GO:0050910
label: detection of mechanical stimulus involved in sensory perception of sound
downstream:
- target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
causal_link_type: DIRECT
hypothesis_groups:
- a211v_mechanotransduction_first
description: >-
Reduced inner hair cell receptor potential is proposed to reduce afferent drive. The model shows
reduced summating and compound action potentials, but does not directly quantify sound-evoked glutamate
release.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
The summating potential was reduced, indicating the alteration of inner hair cell (IHC)
receptor potential.
explanation: >-
The measurement and the authors' own interpretation of it.
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
These results suggest that DFNA25 stems from a failure in the mechano-transduction
followed by a change in synaptic transfer.
explanation: >-
The ordering claim that this hypothesis group is built on, stated by the authors as a
suggestion rather than a demonstration - which is why the group is EMERGING.
- name: Synaptic Ribbon Enlargement
biological_scale: CELLULAR
description: >-
Homozygous A224V inner hair cell ribbons enlarge markedly at four to six months, with preserved ribbon
and synapse counts in the sampled region. This structural change follows early bundle abnormalities.
Its causal contribution to hearing loss, including whether it is compensatory, remains unresolved.
cell_types:
- preferred_term: cochlear inner hair cell
term:
id: CL:0000589
label: cochlear inner hair cell
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
However, synaptic ribbons became abnormally elongated in knock‐in mice
explanation: >-
Mouse cochlear imaging supports ribbon enlargement, not a measured increase in glutamate secretion.
quote_role: PRIMARY_RESULT
directness: DIRECT
- name: Increased Sustained Inner Hair Cell Exocytosis
biological_scale: CELLULAR
description: >-
At six months, freshly dissected homozygous A224V inner hair cells show increased sustained exocytic
capacitance responses to long depolarizations, with preserved calcium currents and readily releasable
pool responses. Capacitance measures membrane fusion rather than vesicular glutamate content or afferent
neurotransmission. The change may reflect compensation or extrasynaptic release; it is not established
as a cause of hearing loss.
cell_types:
- preferred_term: cochlear inner hair cell
term:
id: CL:0000589
label: cochlear inner hair cell
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
patch-clamp membrane capacitance measurements showed an increase in the rate of the sustained releasable
pool exocytosis
explanation: >-
Ex-vivo patch-clamp measurements in isolated mouse organs of Corti; membrane fusion does not determine
glutamate quantal content.
quote_role: PRIMARY_RESULT
directness: DIRECT
- name: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
biological_scale: TISSUE
description: >-
Slc17a8-null mice lack sound-evoked auditory responses while retaining otoacoustic emissions and electrically
evoked brainstem responses. Homozygous A224V mice show progressive auditory threshold elevation with
preserved emissions. Human otoacoustic-emission data are sparse and differ from these model findings;
this node records experimental physiology rather than a universal human diagnostic signature.
cell_types:
- preferred_term: type 1 spiral ganglion neuron
term:
id: CL:4023115
label: type 1 spiral ganglion neuron
- preferred_term: cochlear outer hair cell
term:
id: CL:0000601
label: cochlear outer hair cell
biological_processes:
- preferred_term: sensory perception of sound
modifier: DECREASED
term:
id: GO:0007605
label: sensory perception of sound
locations:
- preferred_term: organ of Corti
term:
id: UBERON:0002227
label: spiral organ of cochlea
downstream:
- target: Secondary Deafferentation of the Inner Hair Cell
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
Loss of afferent signaling and later deafferentation occur in null mice; glutamate also has developmental
effects, so this is not established as a direct use-dependent degeneration mechanism in humans.
- target: Progressive High-Frequency Sensorineural Hearing Loss
causal_link_type: DIRECT
description: >-
Impaired afferent sound encoding provides a model-based explanation for hearing loss. The progressive
human course is not reproduced by the congenitally deaf null model.
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Null mice with a targeted deletion of Slc17a8 exon 2 lacked auditory-nerve responses to
acoustic stimuli, although auditory brainstem responses could be elicited by electrical
stimuli, and robust otoacoustic emissions were recorded.
explanation: >-
All three halves of the dissociation in one sentence: no acoustic neural response,
preserved electrical response, preserved emissions.
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Using auditory brainstem response and distortion product otoacoustic emissions, we
showed progressive hearing loss with intact cochlear amplification in the
VGLUT3A224V/A224V mouse.
explanation: >-
The same dissociation in the allele-matched model, and in progressive rather than
congenital form.
- name: Secondary Deafferentation of the Inner Hair Cell
biological_scale: TISSUE
description: >-
Null mice show loss of afferent synapses, spiral ganglion neurons and lateral efferent endings; some
neuronal loss precedes hearing onset. Older null cochleae also show inner hair cell and stereocilia
degeneration. These observations raise questions about treatment timing, but do not define a human
therapeutic window. Rescue studies in post-neonatal null mice remain distinct from dominant human
disease.
cell_types:
- preferred_term: spiral ganglion neuron
term:
id: CL:0011113
label: spiral ganglion neuron
downstream:
- target: Progressive High-Frequency Sensorineural Hearing Loss
causal_link_type: DIRECT
description: >-
Reduced afferent innervation may contribute to sustained hearing impairment in null models; its
contribution and reversibility in human DFNA25 are unknown.
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Later, the number of afferent synapses, spiral ganglion neurons, and lateral efferent
endings below sensory IHCs declined.
explanation: >-
The deafferentation itself, and its late timing relative to the functional deficit.
- reference: PMID:18215623
reference_title: Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
The early degeneration of some cochlear ganglion neurons in knockout mice also
indicates an important developmental role for the glutamate released by hair cells
before the onset of hearing.
explanation: >-
The developmental component, which is a different claim from use-dependent loss and is
the reason a congenital null and an adult-onset human disease may diverge here.
- reference: PMID:40841774
reference_title: Gene therapy restores auditory function and rescues damaged inner hair cells in an aged Vglut3 knockout mouse model.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
In this study, we analyzed the cochlear structure of aged Vglut3KO mice, revealing
significant degeneration of inner hair cells, synapses, and stereocilia.
explanation: >-
The structural endpoint in the aged null animal.
phenotypes:
- category: Otologic
name: Progressive High-Frequency Sensorineural Hearing Loss
description: >-
Progressive, predominantly high-frequency sensorineural hearing loss is the characteristic presentation
in the founding families. Audiogram shape and severity vary. Family-based ascertainment and a dated
ClinGen proband count do not support a population-wide phenotype frequency.
phenotype_term:
preferred_term: High-frequency sensorineural hearing impairment
term:
id: HP:0001757
label: High-frequency sensorineural hearing impairment
clinical_course: PROGRESSIVE
evidence:
- reference: PMID:11115382
reference_title: "DFNA25, a novel locus for dominant nonsyndromic hereditary hearing impairment, maps to 12q21-24."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
we identified a novel dominant locus, DFNA25, for delayed-onset, progressive,
high-frequency, nonsyndromic sensorineural hearing loss in a large, multigenerational
United States family of Czech descent.
explanation: >-
The phenotype as defined at the locus, in the founding kindred.
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We have identified SLC17A8, which encodes the vesicular glutamate transporter-3
(VGLUT3), as the gene responsible for DFNA25, an autosomal-dominant form of
progressive, high-frequency nonsyndromic deafness.
explanation: >-
The same phenotype restated once the gene was in hand.
- category: Otologic
name: Postlingual Delayed Onset
description: >-
Postlingual onset is typical, not universal. The 2003 full clinical report includes a child whose
loss was suspected at birth and confirmed by diagnostic ABR at three months. A normal newborn screen
cannot exclude later-onset genetic hearing loss.
phenotype_term:
preferred_term: Postlingual sensorineural hearing impairment
term:
id: HP:0008596
label: Postlingual sensorineural hearing impairment
evidence:
- reference: PMID:12925340
reference_title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Affected individuals typically manifest a high-frequency, slowly progressive
sensorineural hearing loss in the postlingual period.
explanation: >-
The abstract explicitly says typically. The primary full text documents an early-onset exception;
normal hearing through speech acquisition is not universal.
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
supports: SUPPORT
evidence_source: OTHER
snippet: >-
In general, autosomal dominant nonsyndromic hearing loss is postlingual, progressive, and high frequency.
explanation: >-
General clinical baseline, not a SLC17A8-specific age distribution or exclusion of congenital presentations.
quote_role: REVIEW_SYNTHESIS
directness: INDIRECT
- category: Otologic
name: Absent Otoacoustic Emissions
description: >-
The 2003 family report documents absent transient-evoked emissions and no repeatable ABR in the proband
III:14. The later knock-in discussion generalizes this to patients, but the primary detailed test
report is not a cohort-wide denominator. No frequency or universal exclusion of auditory neuropathy
is inferred. Acquired cochlear injury and mixed mechanisms remain possible explanations.
phenotype_term:
preferred_term: Absent otoacoustic emissions
term:
id: HP:6000182
label: Absent otoacoustic emissions
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In contrast, otoacoustic emissions were absent in patients harbouring the p.A211V allele
explanation: >-
Secondary discussion of the 2003 human study. Inspection of that primary full text limits the detailed
OAE/ABR observation to the proband; the plural wording is not evidence for prevalence or a universal
classification.
quote_role: BACKGROUND
directness: INDIRECT
- category: Otologic
name: Absence of Syndromic Features
description: >-
The reported Korean splice-variant family had hearing loss without accompanying symptoms. This supports
a nonsyndromic human presentation. Vestibular sparing in null mice is a separate experimental observation
and cannot establish normal vestibular function in every human carrier.
evidence:
- reference: PMID:28647561
reference_title: Identification of a novel splicing mutation within SLC17A8 in a Korean family with hearing loss by whole-exome sequencing.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the clinical information about this family revealed that there are no other symptoms
accompanied with HL
explanation: >-
The nonsyndromic statement in a reported dominant family.
genetic:
- name: SLC17A8
gene_term:
preferred_term: SLC17A8
term:
id: hgnc:20151
label: SLC17A8
relationship_type: CAUSATIVE
notes: >-
SLC17A8 encodes VGLUT3. ClinGen classified its dominant nonsyndromic hearing loss relationship as
Definitive in 2023; the counted probands and variants describe that assessment. A211V, c.616dupA and
c.763+1G>T differ in their supporting segregation and functional evidence. The 2016 frameshift was
found in one sequenced proband with an affected pedigree; the splice report demonstrated cosegregation,
but did not establish transcript consequences in its abstract. The 2021 cell study tested the already
reported c.616dupA alongside c.824C>A, rather than discovering two additional alleles.
evidence:
- reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
reference_title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Variants in this gene segregated with disease in 28 additional members in two families
explanation: >-
The segregation evidence behind the Definitive classification.
- reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
reference_title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
supports: SUPPORT
evidence_source: OTHER
snippet: >-
In summary, SCL17A8 is definitively associated with autosomal dominant nonsyndromic
hearing loss.
explanation: >-
The panel's summary sentence. The gene symbol is transposed in the source record and is
quoted as written.
inheritance:
- name: Autosomal dominant
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
description: >-
Autosomal dominant transmission with age-dependent penetrance. Each child of a heterozygous affected
individual has a 50% chance of inheriting the variant; this is not a 50% probability of hearing loss
at a specified age. Earlier reported onset in males and a maternal-versus-paternal haplotype pattern
arose in one pre-gene-mapping kindred and remain unreplicated modifier hypotheses. Normal hearing
at one assessment does not exclude carrier status. Four tested mitochondrial variants were absent,
which does not exclude all mitochondrial effects.
evidence:
- reference: PMID:12925340
reference_title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The mode of inheritance is autosomal dominant with age-dependent penetrance.
explanation: >-
Inheritance mode and the penetrance qualifier together.
- reference: PMID:12925340
reference_title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In those inheriting the DFNA25-associated haplotype from an affected mother, hearing
loss invariably developed by the second decade of life, whereas those inheriting the
DFNA25 haplotype from an affected father often maintained hearing levels comparable to
those of age-matched control subjects, even into the seventh decade of life.
explanation: >-
The parent-of-origin observation, quoted in full so the size and source of the claim
travel with it.
- reference: PMID:12925340
reference_title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
None of 4 deafness-associated mitochondrial mutations screened (1555A>G, 7445A>G,
Cins7472, and 7511T>C) were found to segregate in the family.
explanation: >-
Only the four tested mitochondrial variants were excluded; the study did not sequence the mitochondrial
genome or establish the cause of the parent-of-origin pattern.
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic
variant to each child.
explanation: >-
General autosomal dominant transmission probability, distinct from penetrance.
quote_role: REVIEW_SYNTHESIS
directness: INDIRECT
animal_models:
- name: Slc17a8 null mouse
species: Mouse
genotype: Slc17a8 (Vglut3) exon 2 targeted deletion, homozygous null
publication: PMID:18674745
description: >-
Homozygous Slc17a8 null mice model complete loss of vesicular glutamate transmission with profound
hearing loss and extra-cochlear effects including seizures. The published vestibular study found strongly
reduced quantal transmission but relatively preserved spontaneous vestibular nerve activity and most
balance tests, with some assay differences. Nonquantal compensation is proposed; this is not proof
of normal human vestibular function.
modeled_mechanisms:
- target: Impaired Glutamate Release at the Inner Hair Cell Ribbon Synapse
relationship: RECAPITULATES
fidelity: MODERATE
description: >-
The release failure and its localisation to vesicle content rather than fusion, both
measured directly in the correct cell type.
limitations: >-
Homozygous null mice model complete VGLUT3 loss, not the heterozygous human genotypes. Congenital
profound deafness and mouse epilepsy do not reproduce the typical progressive nonsyndromic presentation.
readouts:
- name: Calcium-triggered synaptic vesicle turnover in inner hair cells
target: Impaired Glutamate Release at the Inner Hair Cell Ribbon Synapse
direction: UNCHANGED
interpretation: >-
Exocytosis itself is normal. A deliberate negative result, and the one that makes the
defect a cargo defect rather than a release-machinery defect.
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Ca(2+)-triggered synaptic-vesicle turnover was normal in IHCs of Slc17a8 null mice
when probed by membrane capacitance measurements at 2 weeks of age.
explanation: >-
The capacitance measurement behind this readout.
- name: Ribbon synapse ultrastructure at three months
target: Impaired Glutamate Release at the Inner Hair Cell Ribbon Synapse
direction: UNCHANGED
interpretation: >-
Surviving ribbons appeared normal in this line at three months despite reduced synapse numbers.
Other null-model studies reported altered ribbon shape; this result is specific to this study.
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Ribbon synapses remaining by 3 months of age had a normal ultrastructural
appearance.
explanation: >-
The electron-microscopy observation behind this readout.
evidence:
- reference: PMID:18215623
reference_title: Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
We now report that mice lacking VGLUT3 are profoundly deaf due to the absence of
glutamate release from hair cells at the first synapse in the auditory pathway.
explanation: >-
Supports treating this model as informative for the release node.
- target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
relationship: RECAPITULATES
fidelity: MODERATE
description: >-
The three-way dissociation - no acoustic neural response, intact emissions, intact
electrically evoked brainstem response - measured in one animal.
limitations: >-
Detailed human OAE/ABR testing in the 2003 report concerns one proband. The mouse dissociation cannot
establish the physiology of all carriers or clinical implant outcomes.
readouts:
- name: Otoacoustic emissions
target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
direction: UNCHANGED
interpretation: >-
Outer hair cell amplification is preserved, placing the lesion downstream of the
cochlear amplifier. A negative result, and the load-bearing one.
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
robust otoacoustic emissions were recorded
explanation: >-
The emissions measurement behind this readout.
- name: Electrically evoked auditory brainstem response
target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
direction: UNCHANGED
interpretation: >-
The ascending auditory pathway can still be driven when the defective synapse is
bypassed, which is the observation that makes cochlear implantation biologically
plausible in this disease.
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
although auditory brainstem responses could be elicited by electrical stimuli
explanation: >-
The electrical-stimulation measurement behind this readout.
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Null mice with a targeted deletion of Slc17a8 exon 2 lacked auditory-nerve responses
to acoustic stimuli, although auditory brainstem responses could be elicited by
electrical stimuli, and robust otoacoustic emissions were recorded.
explanation: >-
Supports treating this model as informative for the dissociation node.
- target: Secondary Deafferentation of the Inner Hair Cell
relationship: RECAPITULATES
fidelity: LOW
description: >-
The afferent synapses, spiral ganglion neurons and lateral efferent endings decline
after the functional deficit is established.
limitations: >-
The null model has complete congenital loss of signaling and developmental neuronal effects. Human
onset is variable and usually later; human synapse-count evidence is lacking in the reviewed sources.
readouts:
- name: Afferent synapse and spiral ganglion neuron counts
target: Secondary Deafferentation of the Inner Hair Cell
direction: DECREASED
interpretation: >-
The afferent population beneath the inner hair cell falls over time in the null
animal.
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Later, the number of afferent synapses, spiral ganglion neurons, and lateral
efferent endings below sensory IHCs declined.
explanation: >-
The counting result behind this readout.
evidence:
- reference: PMID:18215623
reference_title: Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
The early degeneration of some cochlear ganglion neurons in knockout mice also
indicates an important developmental role for the glutamate released by hair cells
before the onset of hearing.
explanation: >-
Supports the model for this node while naming the developmental confound that limits
its fidelity.
evidence:
- reference: DOI:10.1038/s41598-026-43836-7
reference_title: Persistence of vestibular function in the absence of glutamatergic transmission from hair cells
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
We propose that non-quantal transmission is sufficient to support vestibular nerve physiology and
behavioral function in Vglut3 −/− mice.
explanation: >-
The published study proposes a compensatory explanation from mouse physiology and behavioral tests;
some assay differences and limited sampling preclude universal normality.
quote_role: PRIMARY_RESULT
directness: INDIRECT
- name: VGLUT3 A224V knock-in mouse
species: Mouse
genotype: Slc17a8 p.A224V knock-in (mouse equivalent of human p.A211V), homozygous
publication: PMID:34783032
description: >-
The allele-matched model, and the reason this entry carries two hypothesis groups. A
single point mutation was introduced into exon 5 of mouse Slc17a8, exchanging the codon
for the alanine that corresponds to human A211. It reproduces the progressive course the
null mouse does not, and it reaches a different conclusion about where the disease starts.
modeled_mechanisms:
- target: Inner Hair Cell Stereocilia Bundle Disruption
relationship: RECAPITULATES
fidelity: MODERATE
description: >-
Collapse and fusion of the inner hair cell stereocilia bundles, with outer hair cell
bundles spared - the model's primary structural finding.
limitations: >-
Homozygosity differs from human dominant inheritance. The C57BL/6J Cdh23 background may modify the
bundle phenotype; this has not been separated experimentally. No corresponding human cochlear morphology
was demonstrated.
readouts:
- name: Inner hair cell stereocilia bundle morphology by scanning electron microscopy
target: Inner Hair Cell Stereocilia Bundle Disruption
direction: ALTERED
interpretation: >-
Inner hair cell bundles collapse; outer hair cell bundles do not. The contrast within
the same cochlea is what makes this a cell-type-specific lesion rather than general
degeneration.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Scanning electron microscopy examinations demonstrated the collapse of stereocilia
bundles in IHCs, leaving those from outer hair cells unaffected.
explanation: >-
The microscopy result behind this readout.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
These results suggest that DFNA25 stems from a failure in the mechano-transduction
followed by a change in synaptic transfer.
explanation: >-
The authors' claim that this model's structural finding is the disease's starting
point, which is what makes the model informative for this node.
- target: Reduced Inner Hair Cell Receptor Potential
relationship: RECAPITULATES
fidelity: MODERATE
description: >-
The functional counterpart of the bundle collapse, measured as a reduced summating
potential in an animal whose cochlear amplifier is intact.
limitations: >-
The summating potential is a gross cochlear potential and an indirect index of the
inner hair cell receptor potential rather than a recording from the cell. It is not
measured clinically in DFNA25 patients, so there is no human comparison.
readouts:
- name: Summating potential
target: Reduced Inner Hair Cell Receptor Potential
direction: DECREASED
interpretation: >-
A smaller receptor-potential correlate from a mechanically normal input, consistent
with a transduction rather than an amplification deficit.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
The summating potential was reduced, indicating the alteration of inner hair cell
(IHC) receptor potential.
explanation: >-
The measurement behind this readout.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
The summating potential was reduced, indicating the alteration of inner hair cell (IHC) receptor
potential.
explanation: >-
Measured cochlear potential supports the model-to-mechanism link, with the indirect nature of
the receptor-potential readout stated in its limitations.
- target: Synaptic Ribbon Enlargement
relationship: RECAPITULATES
fidelity: MODERATE
description: >-
Ribbon enlargement at four to six months in the homozygous knock-in.
limitations: >-
Elongated and enlarged ribbons are not necessarily opposite findings. Morphology differs between
studies and models; compensation, pathogenic contribution and relevance to human heterozygotes remain
unresolved.
readouts:
- name: Synaptic ribbon size by super-resolution microscopy
target: Synaptic Ribbon Enlargement
direction: INCREASED
interpretation: >-
Ribbons are larger than wild type in the knock-in animal.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Using super-resolution microscopy, we observed oversized synaptic ribbons
explanation: >-
The imaging result behind this readout.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
In addition, IHC ribbon synapses underwent structural and functional modifications at
later stages.
explanation: >-
Supports the model for this node and fixes its position late in the sequence.
- target: Increased Sustained Inner Hair Cell Exocytosis
relationship: RECAPITULATES
fidelity: MODERATE
description: >-
Increased sustained exocytic capacitance response at six months.
limitations: >-
An ex-vivo membrane-fusion readout, not a direct measure of glutamate release or evidence that increased
secretion causes the hearing deficit.
readouts:
- name: Sustained releasable pool exocytosis rate
target: Increased Sustained Inner Hair Cell Exocytosis
direction: INCREASED
interpretation: >-
Sustained vesicle fusion is increased under imposed depolarization; glutamate quantal content
was not measured.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
patch-clamp membrane capacitance measurements showed an increase in the rate of the
sustained releasable pool exocytosis
explanation: >-
The capacitance measurement behind this readout.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
patch-clamp membrane capacitance measurements showed an increase in the rate of the sustained
releasable pool exocytosis
explanation: >-
Ex-vivo patch-clamp measurements in isolated mouse organs of Corti; membrane fusion does not determine
glutamate quantal content.
quote_role: PRIMARY_RESULT
directness: DIRECT
- target: Progressive High-Frequency Sensorineural Hearing Loss
relationship: PARTIALLY_RECAPITULATES
fidelity: MODERATE
description: >-
Progressive hearing loss with intact cochlear amplification, which is the human course
in outline.
limitations: >-
Homozygotes progress, whereas heterozygotes have only mild impairment over the studied interval.
Human dominant inheritance, audiogram configuration and limited human OAE findings are not fully
reproduced. Lifespan and background effects remain hypotheses.
readouts:
- name: Auditory brainstem response threshold
target: Progressive High-Frequency Sensorineural Hearing Loss
direction: INCREASED
interpretation: >-
Thresholds rise progressively with age. The direction is INCREASED because the
readout is a threshold - worse hearing means more sound is required to evoke a
response.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Mutant mice carrying the VGLUT3-p.A211V variant show progressive hearing loss.
explanation: >-
The progressive threshold shift behind this readout, stated in the paper's key
points.
- name: Distortion-product otoacoustic emissions
target: Progressive High-Frequency Sensorineural Hearing Loss
direction: UNCHANGED
interpretation: >-
Cochlear amplification is intact while brainstem responses deteriorate. A negative
result that separates this from an outer-hair-cell hearing loss.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
we showed progressive hearing loss with intact cochlear amplification in the
VGLUT3A224V/A224V mouse
explanation: >-
The emissions measurement behind this readout.
evidence:
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Our data show that the VGLUT3A224V/A224V mice phenocopy human progressive hearing
loss.
explanation: >-
The authors' own claim that this model matches the human course, which is what
licenses using it for the clinical phenotype node.
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: REFUTE
evidence_source: MODEL_ORGANISM
snippet: >-
the mouse model harbouring the VGLUT3-p.A224V variant mimics a progressive hearing loss
with auditory neuropathy features, but might be arguable so far as to consider it as a
faithful model of DFNA25
explanation: >-
The same authors' qualification of the sentence above, in the discussion rather than the
abstract. It is recorded as REFUTE against the link's claim of fidelity, and it is why
this relationship is PARTIALLY_RECAPITULATES.
- reference: PMID:34783032
reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
However, the mild hearing impairment in the VGLUT3+/A224V heterozygotes contrasts with
the dominant transmission in DFNA25
explanation: >-
The zygosity mismatch measured rather than assumed: the genotype that matches a patient
is only mildly affected in this animal.
diagnosis:
- name: Pure-Tone Audiometry
description: >-
Audiometric assessment documents and tracks the delayed-onset,
progressive, high-frequency-predominant sensorineural hearing loss that
defines DFNA25, as a step separate from the molecular testing described
in the row below.
diagnosis_term:
preferred_term: audiometric test
term:
id: NCIT:C38036
label: Audiometric Test
measurements:
- preferred_term: pure-tone threshold audiometry
term:
id: LOINC:89015-2
label: Pure tone threshold audiometry panel
- preferred_term: hearing threshold, left ear, 500 Hz
term:
id: LOINC:89024-4
label: Hearing threshold Ear - left --500 Hz
- preferred_term: hearing threshold, right ear, 500 Hz
term:
id: LOINC:89025-1
label: Hearing threshold Ear - right --500 Hz
- preferred_term: hearing threshold, left ear, 1000 Hz
term:
id: LOINC:89016-0
label: Hearing threshold Ear - left --1000 Hz
- preferred_term: hearing threshold, right ear, 1000 Hz
term:
id: LOINC:89017-8
label: Hearing threshold Ear - right --1000 Hz
- preferred_term: hearing threshold, left ear, 2000 Hz
term:
id: LOINC:89018-6
label: Hearing threshold Ear - left --2000 Hz
- preferred_term: hearing threshold, right ear, 2000 Hz
term:
id: LOINC:89019-4
label: Hearing threshold Ear - right --2000 Hz
- preferred_term: hearing threshold, left ear, 4000 Hz
term:
id: LOINC:89022-8
label: Hearing threshold Ear - left --4000 Hz
- preferred_term: hearing threshold, right ear, 4000 Hz
term:
id: LOINC:89023-6
label: Hearing threshold Ear - right --4000 Hz
notes: >-
No reference range is recorded: the cited founding-locus report states
the loss is progressive and high-frequency-predominant but gives no
severity grade or dB cut-off specific to DFNA25.
evidence:
- reference: PMID:11115382
reference_title: "DFNA25, a novel locus for dominant nonsyndromic hereditary hearing impairment, maps to 12q21-24."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
we identified a novel dominant locus, DFNA25, for delayed-onset, progressive,
high-frequency, nonsyndromic sensorineural hearing loss in a large, multigenerational
United States family of Czech descent.
explanation: >-
States the progressive, high-frequency-predominant audiometric pattern
that these measurements document and track over serial audiograms.
- name: Molecular testing of SLC17A8
description: >-
Combine audiologic assessment, examination for syndromic findings, family history and molecular testing.
A hearing-loss multigene panel or genomic testing can identify SLC17A8 alongside overlapping causes.
Testing a known familial pathogenic variant clarifies carrier status; audiometry independently measures
current hearing and progression.
evidence:
- reference: PMID:28647561
reference_title: Identification of a novel splicing mutation within SLC17A8 in a Korean family with hearing loss by whole-exome sequencing.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
To identify a causative mutation of HL in this family, we performed whole-exome
sequencing of 4 family members, 3 affected and an unaffected.
explanation: >-
Family exome sequencing identified the splice-site variant; the paper does not state that linkage
was unavailable.
- reference: PMID:26797701
reference_title: Screening of the SLC17A8 gene as a causative factor for autosomal dominant non-syndromic hearing loss in Koreans.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In this study, we performed a genetic analysis of 87 unrelated Korean patients with
ADNSHL to determine whether the SLC17A8 gene affects hearing ability in the Korean
population.
explanation: >-
The screened cohort comprised 87 unrelated dominant-hearing-loss probands; the single candidate
frameshift does not provide a general diagnostic yield.
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Single-gene testing (sequence analysis of a given gene, followed by gene-targeted deletion/duplication
analysis) is rarely useful and typically NOT recommended.
explanation: >-
General initial diagnostic strategy; targeted testing for a known familial variant is a separate
indication.
quote_role: REVIEW_SYNTHESIS
directness: INDIRECT
- name: Variant interpretation as a distinct problem in this gene
description: >-
Evaluate each variant using segregation, population data, phenotype and functional evidence. A VUS
does not confirm or exclude DFNA25. The 2016 full text found I78V did not cosegregate and A374S also
occurred in normal-hearing controls, illustrating why conservation and predictions alone are insufficient.
Cell-culture effects of c.616dupA and c.824C>A are functional support, not proof of a shared mechanism
or clinical pathogenicity.
evidence:
- reference: PMID:34145196
reference_title: "The c.824C>A and c.616dupA mutations in the SLC17a8 gene are associated with auditory neuropathy and lead to defective expression of VGluT3."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Although several suspected pathogenic mutations of the SLC17a8 gene have been
identified in humans, few studies have confirmed their pathogenicity.
explanation: >-
The interpretation problem stated by the authors as their motivation.
- reference: PMID:34145196
reference_title: "The c.824C>A and c.616dupA mutations in the SLC17a8 gene are associated with auditory neuropathy and lead to defective expression of VGluT3."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
The c.616dupA mutation in the SLC17a8 gene resulted in a significant decrease in
transcriptional activity of mRNA, and the expression of VGluT3 was also reduced. The
c.824C>A mutation in the SLC17a8 gene resulted in abnormal VGluT3, although this
mutation did not affect the transcriptional activity of mRNA.
explanation: >-
Two alleles in one gene with two different molecular consequences, measured in cell
culture.
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The identification of variant(s) of uncertain significance cannot be used to confirm or rule out
the diagnosis.
explanation: >-
General variant-interpretation guidance.
quote_role: REVIEW_SYNTHESIS
directness: INDIRECT
treatments:
- name: Hearing Aids
therapeutic_modality: DEVICE
description: >-
Offer audiologist-fitted amplification and communication support according to hearing thresholds,
speech testing and individual preferences. This follows general genetic hearing-loss care; genotype-specific
benefit cannot be predicted from the null mouse or an isolated OAE finding.
treatment_term:
preferred_term: hearing aid fitting
term:
id: NCIT:C15315
label: Rehabilitation
qualifiers:
- predicate:
preferred_term: medical device
term:
id: NCIT:C16830
label: Medical Device
value:
preferred_term: hearing aid
term:
id: NCIT:C183182
label: Hearing Aid
evidence:
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
supports: SUPPORT
evidence_source: OTHER
snippet: >-
customized by an audiologist to the degree and frequency of hearing loss, can be used in individuals
with mild-to-severe hearing loss.
explanation: >-
General hearing-aid guidance, not a DFNA25 outcome estimate.
quote_role: REVIEW_SYNTHESIS
directness: INDIRECT
- name: Cochlear Implantation
therapeutic_modality: DEVICE
description: >-
Consider cochlear implantation under standard audiologic candidacy assessment when amplification provides
insufficient benefit. Preserved electrically evoked responses in null mice provide mechanistic plausibility,
but do not establish human DFNA25 implant efficacy or guarantee preservation of the neural target.
treatment_term:
preferred_term: cochlear device implantation
term:
id: NCIT:C15329
label: Surgical Procedure
qualifiers:
- predicate:
preferred_term: medical device
term:
id: NCIT:C16830
label: Medical Device
value:
preferred_term: cochlear implant
term:
id: NCIT:C157820
label: Cochlear Implant
target_mechanisms:
- target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
treatment_effect: BYPASSES
description: >-
Direct electrical stimulation of the spiral ganglion substitutes for the defective
inner hair cell synapse.
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
although auditory brainstem responses could be elicited by electrical stimuli
explanation: >-
The preserved electrical responsiveness that an implant would exploit. Model evidence
for a human intervention, so the claim in the description is plausibility rather than
efficacy.
evidence:
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Habilitation for hearing loss includes improved access to sound through hearing aids or cochlear
implants
explanation: >-
General habilitation options; no SLC17A8-specific outcome is asserted.
quote_role: REVIEW_SYNTHESIS
directness: INDIRECT
- name: AAV-mediated VGLUT3 Gene Replacement
therapeutic_modality: GENE_THERAPY
description: >-
Preclinical gene replacement has restored auditory responses in homozygous null mice after neonatal
cochlear AAV1 delivery, adult intracisternal delivery through the cochlear aqueduct, and AAV8 injection
at five weeks with assessment 27 weeks later. The latter does not demonstrate reversal after treatment
of already aged animals. These interventions have not established efficacy in dominant A211V disease;
augmentation, suppression or combined strategies require variant-specific testing. No human SLC17A8
interventional study was identified in the reviewed research; the registered NCT01802190 study is
observational.
treatment_term:
preferred_term: gene therapy
term:
id: NCIT:C15238
label: Gene Therapy
target_mechanisms:
- target: Altered VGLUT3 Function in the Inner Hair Cell
treatment_effect: RESTORES
description: >-
Restoring VGLUT3 protein to the inner hair cell addresses the molecular lesion rather
than its consequences - in an animal that has none of the protein to begin with.
evidence:
- reference: PMID:22841313
reference_title: Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Within 2 weeks of AAV1-VGLUT3 delivery, auditory brainstem response (ABR) thresholds
normalize, along with partial rescue of the startle response.
explanation: >-
The functional rescue, in the null mouse.
- reference: PMID:40841774
reference_title: Gene therapy restores auditory function and rescues damaged inner hair cells in an aged Vglut3 knockout mouse model.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Auditory brainstem response (ABR) testing demonstrated restoration of auditory
function following gene therapy.
explanation: >-
Mice were injected at five weeks and evaluated 27 weeks later, so the aged endpoint does not establish
efficacy when treatment starts in aged animals.
evidence:
- reference: PMID:22841313
reference_title: Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
These findings represent a successful restoration of hearing by gene replacement in
mice, which is a significant advance toward gene therapy of human deafness.
explanation: >-
The authors' own framing of how far the result reaches - toward human therapy, not to
it.
- reference: DOI:10.1126/scitranslmed.abq3916
reference_title: Delivery of gene therapy through a cerebrospinal fluid conduit to rescue hearing in adult mice
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
rescued hearing in adult deaf Slc17A8 −/− mice by restoring VGLUT3 protein expression in inner hair
cells
explanation: >-
Primary 2023 adult-null-mouse rescue supporting the CSF-delivery theme in the research report.
quote_role: PRIMARY_RESULT
directness: DIRECT
- name: Audiologic surveillance and noise protection
description: >-
Follow hearing serially and adjust rehabilitation as needed. Avoid repeated loud-noise overexposure
using general hearing-loss guidance. No SLC17A8-specific surveillance interval or proven genotype-specific
noise susceptibility is inferred.
evidence:
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Regular follow up is recommended for all individuals with genetic hearing loss
explanation: >-
General surveillance baseline.
quote_role: REVIEW_SYNTHESIS
directness: INDIRECT
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
supports: SUPPORT
evidence_source: OTHER
snippet: >-
persons with documented hearing loss should be counseled appropriately and repeated overexposure
to loud noises should be avoided.
explanation: >-
General precaution; no demonstrated DFNA25-specific disease-modifying effect.
quote_role: REVIEW_SYNTHESIS
directness: INDIRECT
- name: Genetic counseling
description: >-
Discuss 50% variant transmission per pregnancy, variable onset and penetrance, familial testing and
reproductive options. Counseling should respect individual communication and reproductive preferences.
evidence:
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic
variant to each child.
explanation: >-
General autosomal dominant transmission probability, distinct from penetrance.
quote_role: REVIEW_SYNTHESIS
directness: INDIRECT
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Once the pathogenic variant(s) have been identified in the family, prenatal and preimplantation
genetic testing for genetic hearing loss are possible.
explanation: >-
General reproductive-testing guidance after identification of the familial variant.
quote_role: REVIEW_SYNTHESIS
directness: INDIRECT
treatment_term:
preferred_term: Genetic counseling
term:
id: NCIT:C15240
label: Genetic Counseling
differential_diagnoses:
- name: Presbycusis and noise-induced hearing loss
description: >-
Age-related and noise-related hearing loss can resemble DFNA25. Pedigree information and molecular
testing help distinguish causes, while acquired exposures and genetic disease may coexist. Audiogram
shape alone is insufficient.
evidence:
- reference: PMID:12925340
reference_title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It is difficult to differentiate delayed-onset high-frequency sensorineural hearing
loss inherited as a simple mendelian trait like DFNA25-associated hearing loss from
that due to noise exposure or presbycusis, disorders that may also have a genetic
component.
explanation: >-
The difficulty stated as the study's own conclusion.
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Autosomal-dominant sensorineural hearing loss is genetically heterogeneous, with a
phenotype closely resembling presbycusis, the most common sensory defect associated
with aging in humans.
explanation: >-
The same resemblance stated for the dominant class DFNA25 belongs to.
quote_role: BACKGROUND
- name: OTOF-related auditory neuropathy (DFNB9)
description: >-
OTOF-related hearing loss is a presynaptic disorder with recessive inheritance, contrasting with dominant
SLC17A8 disease. Typical clinical patterns can guide testing, but overlapping and atypical presentations
require molecular interpretation. Null-mouse physiology and sparse human emission data do not reliably
distinguish every patient.
evidence:
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Null mice with a targeted deletion of Slc17a8 exon 2 lacked auditory-nerve responses to
acoustic stimuli, although auditory brainstem responses could be elicited by electrical
stimuli, and robust otoacoustic emissions were recorded.
explanation: >-
The physiological pattern DFNA25's null mouse shares with the OTOF synaptopathies, which
is what makes DFNB9 the mechanistic differential.
- name: CABP2-related nonsyndromic hearing loss (DFNB93)
description: >-
CABP2-related DFNB93 is recessive and involves regulation of presynaptic calcium channels. Preserved
emissions in a reported CABP2 patient support a synaptopathy in that case; comprehensive emission
phenotyping remains limited. The isolated absent-emission observation in DFNA25 is insufficient for
a universal mechanistic contrast.
evidence:
- reference: PMID:40927552
reference_title: "Is CABP2-Associated Hearing Loss (DFNB93) a Gene Therapy Target? Preclinical Progress and Patient Registry."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Otoacoustic emissions have been observed in an Italian family with a homozygous CABP2
variant, indicating preservation of outer hair cell-mediated cochlear amplification.
explanation: >-
A review summarizes a human CABP2 observation; it does not establish uniform emissions across either
disease.
quote_role: REVIEW_SYNTHESIS
directness: INDIRECT
- reference: PMID:18674745
reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We have identified SLC17A8, which encodes the vesicular glutamate transporter-3
(VGLUT3), as the gene responsible for DFNA25, an autosomal-dominant form of
progressive, high-frequency nonsyndromic deafness.
explanation: >-
Dominant inheritance and the characteristic high-frequency pattern help frame the differential;
the quote does not establish universal postlingual onset.
discussions:
- discussion_id: mismatch_zygosity_of_the_dfna25_mouse_models
kind: HUMAN_MODEL_MISMATCH
status: OPEN
attaches_to:
- pathophysiology#Heterozygous SLC17A8 Variant
- animal_models#VGLUT3 A224V knock-in mouse
prompt: >-
Does either mouse model DFNA25, when both are homozygous and the heterozygote - the
genotype a patient actually has - is only mildly affected?
rationale: >-
Homozygous knock-in mice have progressive impairment but heterozygotes have only mild changes over
six months. Lifespan, allele dose, genetic background and species-specific biology may contribute.
Null rescue does not select the optimal strategy for dominant human alleles.
proposed_experiments:
- experiment_id: dfna25_aged_heterozygous_knockin
name: Lifespan-long auditory phenotyping of heterozygous VGLUT3 A224V mice
description: >-
Follow heterozygous A224V and wild-type littermates across age with serial ABR, emissions and bundle
morphology, accounting for background-related hearing loss.
would_support:
- pathophysiology#Heterozygous SLC17A8 Variant
supporting_outcome:
- A widening deficit would support age-dependent expression in this mouse model, without proving that homozygous pathology transfers to humans.
refuting_outcome:
- A plateau would argue against continued progression under the tested conditions; it would not establish universal tolerance of one allele.
- discussion_id: gap_why_patient_emissions_are_absent
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- phenotypes#Absent Otoacoustic Emissions
- mechanistic_hypotheses#presynaptic_glutamate_loading_failure
prompt: >-
How representative is the absent-emission finding in the original DFNA25 proband?
rationale: >-
The detailed primary human observation concerns one proband, while both main mouse models retain emissions.
Broader human OAE, cochlear microphonic, ABR, age and exposure data are needed to separate cochlear
and neural contributions. Controlled mouse noise experiments can test model susceptibility but cannot
establish the cause of human findings.
proposed_experiments:
- experiment_id: dfna25_noise_vulnerability_by_allele_dose
name: Noise vulnerability in mice carrying one or two VGLUT3-p.A224V alleles
description: >-
Expose wild-type, heterozygous and homozygous A224V mice to a controlled acoustic
overexposure and compare distortion-product emission loss and threshold shift against
unexposed littermates. This is the experiment the knock-in authors name as necessary to
determine whether acoustic injury accounts for the discrepancy between mouse and patient
emissions.
would_support:
- phenotypes#Absent Otoacoustic Emissions
supporting_outcome:
- Greater emission loss after controlled noise would support genotype-dependent susceptibility in mice and motivate human exposure studies.
refuting_outcome:
- No genotype difference would weaken this model-specific noise hypothesis under the tested exposure; it would not resolve human auditory-neuropathy classification.
- discussion_id: gap_where_the_dfna25_lesion_starts
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- mechanistic_hypotheses#presynaptic_glutamate_loading_failure
- mechanistic_hypotheses#a211v_mechanotransduction_first
prompt: >-
How does a vesicular glutamate transporter variant collapse the inner hair cell stereocilia
bundle?
rationale: >-
A224V mice show bundle collapse despite retained transport in heterologous systems and comparable
cochlear VGLUT3 immunofluorescence. Proteostasis, trafficking and the Cdh23 background remain candidate
contributors. Identifying the mechanism could guide therapy, but a gene-directed intervention might
affect both bundle and synaptic consequences.
proposed_experiments:
- experiment_id: dfna25_vglut3_localisation_in_knockin_hair_cells
name: Subcellular localisation and turnover of VGLUT3-p.A224V in inner hair cells
description: >-
Track variant VGLUT3 in knock-in inner hair cells by immunogold electron microscopy and
pulse-chase, testing directly whether it accumulates in the soma or apical compartment,
whether proteostasis markers are engaged, and whether the cuticular plate cytoskeleton is
disturbed before the bundles collapse.
would_support:
- mechanistic_hypotheses#a211v_mechanotransduction_first
supporting_outcome:
- Accumulation and proteostasis changes preceding bundle collapse would support this candidate mechanism; perturbation and rescue would be needed to test causation.
refuting_outcome:
- Normal localization and turnover would weaken this mechanism without excluding other allele-dependent or background effects.
- discussion_id: gap_dfna25_allele_class_heterogeneity
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- genetic#SLC17A8
prompt: >-
Do the truncating and splice SLC17A8 alleles cause the same disease as the missense
founder allele?
rationale: >-
Missense, frameshift and splice alleles have unequal human and functional evidence. The frameshift
and c.824C>A expression study retested reported alleles. Allelic heterogeneity does not by itself
justify splitting a disease, and a normal heterozygous-null mouse does not resolve the human dominant
mechanism.
proposed_experiments:
- experiment_id: dfna25_allele_class_audiogram_comparison
name: Audiometric comparison of missense against truncating SLC17A8 carriers
description: >-
Collect audiograms and ages at onset across all published SLC17A8 heterozygotes and
compare the founder missense families against the frameshift and splice-donor families,
testing whether onset, progression rate and audiometric shape differ by allele class.
would_support:
- genetic#SLC17A8
supporting_outcome:
- Overlapping profiles would support shared clinical features without proving a shared molecular mechanism.
refuting_outcome:
- Reproducible differences would support allele-specific prognosis and further mechanistic work, without by themselves requiring separate disease entities.
notes: >-
This is a genetic disease eligible for review despite noise exposure being a possible modifier and differential.
SLC17A8 and the auditory brainstem response abbreviation ABR were distinguished in the research preflight;
ABR is not a rival causal gene here. The matching research narrative, table, bibliography and citation
sidecar were assessed. The report misidentifies PMID:22794260 as the 2012 rescue study; the correct
PMID:22841313 is retained. Incorrect suggested HPO bindings were not imported. Normal-cell vesicle proteomics
is background, not a disease biomarker. Adult CSF-mediated null-mouse rescue is now represented with
the primary 2023 citation.
The full GeneReviews Genetic Hearing Loss Overview supplies general clinical, diagnostic, management,
surveillance and counseling context; it is not a DFNA25-specific chapter and does not establish gene-specific
phenotype frequencies or follow-up intervals. Dated ClinGen counts are not worldwide prevalence. No
quantitative progression rate is inferred from a single-family serial-audiogram report.
The 2003 JAMA primary full text was inspected online. Automated cache retrieval returned 403 for HTML
and PDF, so cached abstract quotations and the explicitly secondary OAE quotation are retained without
inventing a full-text cache. The full text narrows the OAE/ABR denominator and documents an early-onset
exception. Absence of emissions alone does not settle the disease classification.
The PMID:41279968 cache combines a 2025 preprint abstract with the later published PDF. The published
vestibular study is cited separately by DOI:10.1038/s41598-026-43836-7; its mouse findings are not human
phenotype evidence. Full-text discussion limits apparently spared balance to the assays tested and proposes,
rather than proves, nonquantal compensation.
references:
- reference: PMID:18674745
title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
- reference: PMID:12925340
title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
- reference: PMID:11115382
title: "DFNA25, a novel locus for dominant nonsyndromic hereditary hearing impairment, maps to 12q21-24."
- reference: PMID:34783032
title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
- reference: PMID:18215623
title: Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3.
- reference: PMID:22841313
title: Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy.
- reference: PMID:40841774
title: Gene therapy restores auditory function and rescues damaged inner hair cells in an aged Vglut3 knockout mouse model.
- reference: PMID:26797701
title: Screening of the SLC17A8 gene as a causative factor for autosomal dominant non-syndromic hearing loss in Koreans.
- reference: PMID:28647561
title: Identification of a novel splicing mutation within SLC17A8 in a Korean family with hearing loss by whole-exome sequencing.
- reference: PMID:40927552
title: "Is CABP2-Associated Hearing Loss (DFNB93) a Gene Therapy Target? Preclinical Progress and Patient Registry."
- reference: PMID:34145196
title: "The c.824C>A and c.616dupA mutations in the SLC17a8 gene are associated with auditory neuropathy and lead to defective expression of VGluT3."
- reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
tags:
- GeneReviews
- reference: DOI:10.1038/s41598-026-43836-7
title: Persistence of vestibular function in the absence of glutamatergic transmission from hair cells
- reference: DOI:10.1126/scitranslmed.abq3916
title: Delivery of gene therapy through a cerebrospinal fluid conduit to rescue hearing in adult mice
- reference: clinicaltrials:NCT01802190
title: Prevalence of POU4F3 (DFNA15) and SLC17A8 (DFNA25) Genes Mutations in Dominant Autosomal Deafness and Phenotypic Characterization of Carrier Patients.
clinical_trials:
- name: NCT01802190
phase: NOT_APPLICABLE
description: >-
Observational genetic screening and phenotypic characterization of SLC17A8/DFNA25 and POU4F3/DFNA15
in dominant hearing loss. This registration does not test a therapy or establish clinical efficacy.
evidence:
- reference: clinicaltrials:NCT01802190
reference_title: Prevalence of POU4F3 (DFNA15) and SLC17A8 (DFNA25) Genes Mutations in Dominant Autosomal Deafness and Phenotypic Characterization of Carrier Patients.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The study will allow to identify the prevalence of the SLC17A8 gene mutations in patients suffering
from deafness.
explanation: >-
Registry summary describes an observational research aim, not a reported prevalence or treatment
result.
status: TERMINATED
notes: 'ClinicalTrials.gov API checked 2026-09-23: observational study, actual enrollment 50; record last updated July 2015 and terminated with no convincing results reported as the reason. Registration is not evidence of a measured DFNA25 prevalence.'
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Create: Autosomal Dominant Nonsyndromic Hearing Loss 25 (DFNA25, SLC17A8/VGLUT3) · 2026-09-02T03:47:22Z · View source
New Disease entry for MONDO:0011568 (DFNA25), curated from primary literature plus a falcon deep-research run (preflight WARN, exit 0; the 'ABR' rival-gene warning is the auditory brainstem response acronym, a false positive). entry_type decision: DISEASE. MONDO:0011568 was bound nowhere in kb/, DFNA25 has its own OMIM phenotype entry, DFNA locus number and a ClinGen Definitive gene-disease assertion, and no existing entry binds SLC17A8, so there was no coverage to duplicate. The stub was deleted. Relationship to the two neighbouring entries, which was the substantive question on the issue. DFNA25 is NOT recorded as a subtype of Auditory_Neuropathy. The defining physiological signature of that class - preserved otoacoustic emissions with an abnormal auditory brainstem response - is demonstrated only in the Slc17a8-null and A224V knock-in mice and has never been measured in a DFNA25 patient. The Auditory_Neuropathy has_subtypes list is populated by entities whose classification rests on a human clinical finding (OTOF, DIAPH3, ATP11A, AIFM1, TMEM43). The contrast with Autosomal_Recessive_Nonsyndromic_Hearing_Loss_93 (CABP2) is recorded explicitly in a differential_diagnoses entry and in notes: DFNB93 has a published human emissions observation and therefore states its synaptopathy classification in its pathophysiology, while DFNA25 states the dissociation for the mouse only and carries the human question as an open KNOWLEDGE_GAP. Two mechanistic_hypotheses groups are curated rather than one, because the two mouse models disagree. The Slc17a8 null (presynaptic_glutamate_loading_failure, CANONICAL) shows empty-vesicle release with normal exocytosis. The allele-matched VGLUT3 A224V knock-in (a211v_mechanotransduction_first, EMERGING) reports inner hair cell stereocilia collapse and a reduced summating potential first, with ribbon changes later, and its authors conclude DFNA25 begins in mechanotransduction. A HUMAN_MODEL_MISMATCH discussion records the genetics problem: heterozygous Slc17a8 knockout mice hear normally while heterozygous human p.A211V carriers go deaf, so neither model matches the patients' genotype and the choice between gene addition and allele-selective knockdown is unresolved. functional_impact_category is deliberately left empty on the trigger node for the same reason. Correction made later in the same session, after the entry was first written. The full text of PMID:34783032 was searched for the heterozygous-mouse phenotype and turned up something more important: otoacoustic emissions are reported ABSENT in p.A211V patients - the opposite of both mouse models - and that paper concludes on that basis that DFNA25 is more likely a progressive hearing loss than an auditory neuropathy. The first draft of this entry asserted that patient emissions had never been measured, which was wrong. The correction strengthens the disposition rather than changing it: DFNA25 stays out of the Auditory_Neuropathy has_subtypes list, now for a positive cited reason rather than for absence of evidence. Added an 'Absent Otoacoustic Emissions' phenotype (HP:6000182) carrying the finding, the authors' classification conclusion, and their untested alternative explanation (lifetime noise exposure) as a NO_EVIDENCE item; added a REFUTE evidence item against the preserved-amplification pathophysiology node; and replaced the lesion-site knowledge gap with two better ones - why patient emissions are absent, and how a vesicular transporter variant collapses a stereocilia bundle it is not present in. The same full-text search also replaced an unsourced prose claim. The first draft said heterozygous Slc17a8 KNOCKOUT mice hear normally, which could not be quoted from any cached reference. The citable fact is better: heterozygous A224V KNOCK-IN mice - the genotype that matches a patient - show only mild impairment, which the authors themselves say contrasts with the dominant transmission in the human families. The HUMAN_MODEL_MISMATCH was rewritten around that and its proposed experiment changed, because the experiment the first draft proposed had already been done. Process note worth recording: the correction took two commits because the first edit script aborted partway on a failed string match and wrote nothing, so two passages - the notes paragraph and the DFNB93 differential - kept the pre-correction wording while the rest of the entry had moved. Grepping the file for the stale phrase is what caught it. After any script-driven edit, confirm the change landed rather than assuming the script ran to completion. Review round (ai4c-reviewer). The first run approved at 45a4e221bc; a re-run of the same check on the same commit returned CHANGES_REQUESTED, so the later verdict was treated as live rather than stale after confirming both reviews carry the head SHA. One blocking item, verified before acting and correct: Cochlear Implantation bound only NCIT:C15329 Surgical Procedure while Hearing Aids in the same file attached the NCIT:C16830 -> NCIT:C183182 device qualifier pair, so the file was inconsistent with itself and NCIT:C157820 was unreachable from the entry. CLAUDE.md names cochlear implantation as the worked case for exactly this pattern and fifteen entries already follow it. Added the qualifier pair; just check-qualifier-terms-online passes (325 labels matched, 97 resolved online). Two suggestions taken. The DFNB93 differential argued a contrast whose DFNB93 half - emissions present - was unsourced in this file; it now cites PMID:40927552 for the Italian family observation, so both halves of the comparison carry evidence. And the notes now close the GeneReviews loop: there is no SLC17A8 or DFNA25 chapter, and the adjacent Genetic Hearing Loss Overview (PMID:20301607) is deliberately not tagged because the cached record does not mention SLC17A8, DFNA25 or VGLUT3 - tagging it would assert a coverage relationship the source does not have. Two suggestions declined with reasons on the PR: noise exposure stays out of environmental: because the entry treats it as an open question in a knowledge gap rather than an asserted exposure, and adding it would assert what the gap exists to ask; and the DR-surfaced supportive-care items are neither DFNA25-specific nor snippet-supportable. Process note from this round: an edit anchored on '- reference: PMID:34145196' matched inside an indented evidence block before reaching the top-level references: list, producing invalid YAML. Caught by running the validator rather than trusting the script's success. Anchor on a line-start pattern and assert the match count. Deliberately absent: no prevalence (nine probands worldwide), no phenotype frequency bands (no denominator that is DFNA25), no progression, no clinical_trials, no datasets. Ontology note: the deep-research report proposed HP:0012715 as 'Bilateral hearing impairment' (it is Profound hearing impairment) and HP:0002066 as 'Hearing impairment' (it is Gait ataxia). Both were caught by resolving through OLS and were not used. Validation: just validate exit 0 (65/65 snippets verified), just validate-terms exit 0, check-duplicate-keys / check-entity-refs / check-causal-targets all exit 0.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Autosomal Dominant Nonsyndromic Hearing Loss 25 covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Present this section as an ordered causal chain first, then the detail below. Open with a numbered sequence of mechanistic steps running from the initiating lesion (mutation, exposure, infection) to the clinical manifestation, one step per line, each naming what it causes next. State the causal verb explicitly ("leads to", "results in") and say where a step is inferred rather than demonstrated. Where the mechanism branches, show the branch. The categories below are a checklist of what to cover within those steps, not the organizing structure — a step may draw on several of them, and a category may contribute to several steps.
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Autosomal dominant nonsyndromic hearing loss 25 (DFNA25) is a very rare, progressive, predominantly high-frequency sensorineural hearing loss caused by heterozygous pathogenic variants in SLC17A8, which encodes vesicular glutamate transporter 3 (VGLUT3/VGluT3). VGLUT3 loads glutamate into synaptic vesicles of cochlear inner hair cells (IHCs), enabling transmission from IHC ribbon synapses to type I spiral-ganglion neurons. Human evidence remains limited to a small number of families, so disease-specific prevalence, quantitative penetrance, progression rates, and quality-of-life statistics are not established. The strongest therapeutic evidence is preclinical: AAV-mediated VGLUT3 replacement has restored hearing in neonatal and adult Slc17a8-null mice, but no DFNA25-specific human gene-therapy trial or approved disease-modifying drug was identified.
The following table provides an ontology-ready synopsis.
| domain | established finding | evidence type | suggested ontology terms/IDs | key evidence |
|---|---|---|---|---|
| disease identifier | Autosomal Dominant Nonsyndromic Hearing Loss 25 (DFNA25) is a Mendelian deafness entity linked to SLC17A8 | Human pedigree/genetic discovery | MONDO:0011568; OMIM 605583 | DFNA25 described as an "autosomal-dominant form of progressive, high-frequency nonsyndromic deafness" caused by SLC17A8 mutation (ruel2008impairmentofslc17a8 pages 1-2) |
| causal gene/protein | SLC17A8 encodes vesicular glutamate transporter 3 (VGLUT3) | Human, mouse, review | SLC17A8; VGLUT3; OMIM 607557 | VGLUT3 loads glutamate into inner hair cell synaptic vesicles before release to auditory nerve terminals (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2) |
| synonyms | DFNA25; deafness, autosomal dominant 25; SLC17A8-related autosomal dominant nonsyndromic hearing loss | Aggregated disease/gene nomenclature with primary literature support | OMIM 605583; SLC17A8-related hearing loss | Primary papers and reviews use DFNA25 / deafness, autosomal dominant 25 terminology (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2) |
| pathogenic variants | Reported disease-associated variants include c.632C>T (p.A211V), p.M206Nfs*4, and c.763+1G>T | Human genetic studies | HGVS nomenclature where known; ACMG classification not uniformly published | p.A211V segregated in two unrelated families and was absent in 267 controls; p.M206Nfs*4 absent in 100 controls; c.763+1G>T co-segregated in a 3-generation Korean family (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2, ryu2017identificationofa pages 1-6) |
| inheritance | Inheritance is autosomal dominant | Human pedigree | HP:0000006 Autosomal dominant inheritance | Multiple families showed autosomal-dominant segregation (ruel2008impairmentofslc17a8 pages 1-2, ryu2017identificationofa pages 1-6) |
| core phenotype | Progressive high-frequency sensorineural hearing loss, nonsyndromic | Human clinical | HP:0000407 Sensorineural hearing impairment; HP:0002066 Hearing impairment; high-frequency qualifier if used in HPO mapping | Human families had delayed/progressive high-frequency SNHL without syndromic features (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2) |
| onset/natural history | Typically delayed/late onset with age-related penetrance increase and progression over time | Human pedigree/clinical | HPO terms for progressive hearing impairment; adult/late onset descriptors as appropriate | DFNA phenotypes are described as delayed-onset and progressive; DFNA25 specifically showed age-related penetrance increase (ruel2008impairmentofslc17a8 pages 1-2, ruel2008impairmentofslc17a8 pages 13-14, ryu2016screeningofthe pages 1-2) |
| syndromic status | No consistent extra-auditory syndromic findings established | Human clinical | HP:0000007 Autosomal dominant inheritance; nonsyndromic descriptor | Korean family report noted hearing loss was non-syndromic with no accompanying symptoms (ryu2017identificationofa pages 1-6) |
| primary anatomy | Primary site is the cochlea, especially the organ of Corti inner hair cell synapse | Human-mechanistic inference supported by mouse and expression data | UBERON: cochlea; organ of Corti; inner hair cell | VGLUT3 is selectively expressed in cochlear inner hair cells and mediates afferent transmission (ryu2016screeningofthe pages 1-2, ruel2008impairmentofslc17a8 pages 1-2) |
| affected cells | Inner hair cells are primary; type I spiral ganglion neuron afferents are secondarily affected | Mouse physiology/morphology with human disease relevance | CL: inner hair cell; spiral ganglion neuron | Slc17a8-null mice lacked acoustic auditory-nerve responses and later showed decline in afferent synapses and spiral ganglion neurons (ruel2008impairmentofslc17a8 pages 1-2, ruel2008impairmentofslc17a8 pages 13-14) |
| subcellular localization | VGLUT3 localizes to synaptic vesicle-like glutamatergic organelles/ribbon-synapse trafficking compartments in IHCs | Proteomics, prior functional work | GO cellular component: synaptic vesicle; presynaptic active zone; synaptic ribbon | 2024 proteomics isolated "VGluT3-containing membrane vesicles" from IHCs and profiled ribbon-synapse trafficking machinery (cepeda2024proteomicanalysisreveals pages 1-3) |
| mechanism | Impaired vesicular glutamate loading/release at the IHC ribbon synapse leads to failure of auditory nerve activation; downstream synapse and neuron loss can follow | Human genetic inference plus mouse functional demonstration | GO: glutamate transport; chemical synaptic transmission; synaptic vesicle cycle | Null mice had absent acoustically evoked ABRs but preserved electrically evoked ABRs and otoacoustic emissions, supporting a synaptic glutamate-release defect rather than OHC failure (ruel2008impairmentofslc17a8 pages 1-2, ruel2008impairmentofslc17a8 pages 13-14) |
| variant-specific mechanism | The human p.A211V allele is modeled by mouse p.A224V and is associated with IHC stereocilia collapse, reduced summating potential, and oversized synaptic ribbons | Mouse knock-in model of human allele | GO: mechanotransduction; synaptic transmission; hair bundle organization | Knock-in mice showed progressive hearing loss with intact cochlear amplification, IHC bundle collapse, and altered ribbon exocytosis, suggesting mechanotransduction failure followed by altered synaptic transfer (joshi2021vglut3‐p.a211vvariantfuses pages 1-2) |
| diagnostic testing | Diagnosis relies on audiologic evaluation plus molecular testing (single gene, deafness panel, WES/WGS depending context) | Clinical genetics practice supported by gene-specific reports | SLC17A8 sequencing; hereditary hearing loss panel | SLC17A8 mutations were identified by candidate-gene sequencing and by whole-exome sequencing in affected families (ryu2016screeningofthe pages 1-2, ryu2017identificationofa pages 1-6) |
| electrophysiology | ABR is abnormal from failed acoustic neural transmission; OAE/DPOAE may remain preserved when OHC function is intact | Mouse functional evidence; clinically relevant inference | ABR; otoacoustic emissions | Slc17a8-null mice lacked auditory-nerve responses to sound yet retained robust otoacoustic emissions; p.A224V model had progressive ABR loss with intact DPOAEs (ruel2008impairmentofslc17a8 pages 1-2, joshi2021vglut3‐p.a211vvariantfuses pages 1-2) |
| treatment status | No DFNA25-specific approved molecular therapy identified; current real-world care is supportive/rehabilitative (hearing aids, cochlear implantation as indicated) | Review plus mechanistic/animal evidence | NCIT: Hearing Aid; Cochlear Implantation | Reviews note hearing aids and cochlear implants remain standard care for hereditary deafness; SLC17A8-specific therapy remains preclinical (duhon2024genetherapyadvancements pages 4-5, zhang2024aav‐mediatedgenetherapy pages 3-4) |
| cochlear implant implication | Because neural responses to electrical stimulation are preserved in Slc17a8-null mice, cochlear implantation is considered biologically plausible | Mouse translational inference | NCIT: Cochlear Implantation | Electrically evoked ABRs were preserved in null mice, suggesting bypass of the defective IHC synapse may help (ruel2008impairmentofslc17a8 pages 13-14) |
| gene therapy/preclinical | AAV1-VGLUT3 cochlear delivery rescued hearing in Vglut3 knockout mice; early postnatal RWM delivery achieved 100% normal ABR threshold recovery in one series | Mouse preclinical interventional | AAV gene replacement; VGLUT3 gene augmentation | Akil 2012 reported normalized ABR thresholds within 2 weeks; P1-P3 RWM delivery rescued 19/19 mice and some maintained hearing long term (akil2012restorationofhearing pages 1-2, akil2012restorationofhearing pages 6-8) |
| mature-cochlea translational development | 2023 mature-mouse CSF/cisterna magna delivery of AAV-PHP.B-CBA-VGLUT3-WPRE reportedly restored hearing in SLC17A8-/- mice except at 40 kHz | Review summarizing preclinical primary study | AAV-PHP.B; cisterna magna delivery | 2024 review summarizes mature-mouse rescue at dose 2.27 × 10^11 vg with limited off-target expression reported (duhon2024genetherapyadvancements pages 11-12) |
| human trials status | No human interventional trial specific to SLC17A8/DFNA25 was identified in the tool-based search | Trial search / evidence gap | ClinicalTrials.gov status: none identified for this gene-disease pair | Recent reviews discuss human OTOF trials, not SLC17A8-specific trials; trial search returned no relevant SLC17A8 intervention (zhang2024aav‐mediatedgenetherapy pages 3-4, duhon2024genetherapyadvancements pages 4-5) |
| model organisms | Key models are Slc17a8 knockout mice and VGLUT3A224V/A224V knock-in mice modeling human p.A211V | Mouse in vivo models | MGI/IMSR resources if needed; Slc17a8 mouse models | Knockout demonstrates synaptic glutamate-release failure; knock-in models progressive/mechanosensory and synaptic pathology (ruel2008impairmentofslc17a8 pages 1-2, joshi2021vglut3‐p.a211vvariantfuses pages 1-2) |
| comparative conservation | The affected alanine residue is conserved across species and among human VGLUT paralogs | Human/mouse comparative sequence evidence | conserved residue annotation | Conservation of A211 supported pathogenic relevance of p.A211V (ruel2008impairmentofslc17a8 pages 1-2) |
| epidemiology | Disease-specific prevalence, incidence, sex ratio, and carrier frequency are not established in the retrieved DFNA25-specific literature | Explicit data gap | not available | Available papers are family-based discovery/screening studies rather than population epidemiology (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2) |
| penetrance/expressivity | Penetrance appears age-dependent and expressivity likely variable, but robust quantitative estimates are lacking | Human pedigree with data gap | age-dependent penetrance descriptor | Human paper notes age-related penetrance increase; no precise percent penetrance estimate retrieved (ruel2008impairmentofslc17a8 pages 13-14) |
| environmental modifiers | No DFNA25-specific environmental risk or protective modifiers were established in retrieved primary disease papers | Explicit data gap | not available | Reviews discuss generic contributors to hearing loss (noise, aging), but not validated DFNA25-specific gene-environment interactions (ruel2008impairmentofslc17a8 pages 1-2, bottom2024defectsinhair pages 1-2) |
| QoL/prognosis gap | No DFNA25-specific quality-of-life or life-expectancy studies were identified; morbidity is expected to derive mainly from chronic progressive hearing impairment | Explicit data gap with general clinical inference | hearing-disability QoL instruments if studied in future | Family reports focus on hearing phenotype/genetics, not QoL or survival outcomes (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2) |
Table: This table condenses the most actionable, ontology-ready facts for DFNA25/SLC17A8-related hearing loss, including core identifiers, phenotype, mechanism, models, and treatment status. It also flags major evidence gaps where disease-specific epidemiology, modifiers, and outcomes are not yet established.
DFNA25 is an inherited, nonsyndromic cochlear disorder characterized by progressive high-frequency sensorineural hearing impairment. The landmark report described it as an “autosomal-dominant form of progressive, high-frequency nonsyndromic deafness.” (ruel2008impairmentofslc17a8 pages 1-2)
The foundational human evidence came from pedigrees, clinical audiometry, linkage analysis, and germline DNA sequencing—not individual EHR-derived records. The broader identifiers and nomenclature are aggregated disease-level annotations.
The discovery article was published 8 August 2008 in the American Journal of Human Genetics, DOI 10.1016/j.ajhg.2008.07.008, PMID 18674745. Its abstract states: “We have identified SLC17A8…as the gene responsible for DFNA25.” (ruel2008impairmentofslc17a8 pages 1-2)
The primary cause is a heterozygous germline SLC17A8 variant affecting VGLUT3. The best-established allele, NM_139319.2:c.632C>T, p.(Ala211Val), segregated with hearing loss in two nominally unrelated families and was absent from 267 controls; linkage-disequilibrium analysis suggested distant common ancestry. The alanine is conserved across species and all three human VGLUT paralogs. (ruel2008impairmentofslc17a8 pages 1-2)
Additional reported alleles include:
These are germline, not somatic, variants. Population allele frequencies were not supplied in the retrieved primary evidence; contemporary gnomAD frequencies and transcript-normalized HGVS should be obtained directly before clinical interpretation.
Simple haploinsufficiency is unlikely to explain every DFNA25 allele: heterozygous Slc17a8 knockout mice have normal hearing and anatomy, whereas humans heterozygous for p.A211V develop age-dependent disease. This supports an allele-specific dominant-negative or toxic gain-of-function mechanism for p.A211V, although the precise molecular interaction remains unresolved. Truncating and splice variants may act differently, and pathogenicity should therefore be evaluated allele by allele. (ruel2008impairmentofslc17a8 pages 13-14)
No replicated modifier gene, protective SLC17A8 allele, epigenetic modifier, founder frequency, or germline-mosaicism estimate has been established. Family history is the major ascertainable risk factor; each child of a heterozygous affected person has a 50% transmission probability, although age-dependent penetrance complicates phenotype-based testing.
Noise, aging, and ototoxic agents are established general causes or accelerants of cochlear synaptopathy, but no study has quantified a DFNA25-specific interaction. Recent work notes that genetic defects, loud noise, ototoxic drugs, and aging can all compromise IHC synaptic sound encoding. Consequently, noise and ototoxin avoidance is biologically reasonable but not proven to alter DFNA25 natural history. (bottom2024defectsinhair pages 1-2, cepeda2024proteomicanalysisreveals pages 1-3)
No specific diet, exercise program, supplement, vaccine, or medication has been demonstrated to prevent genetically initiated DFNA25.
The principal phenotype is bilateral, nonsyndromic, sensorineural hearing impairment, initially most prominent at high frequencies and progressive with age. Onset is generally delayed rather than congenital in the original p.A211V families, and penetrance rises with age. Severity and onset vary among carriers; robust percentages and annual threshold-shift estimates are unavailable. (ruel2008impairmentofslc17a8 pages 1-2, ruel2008impairmentofslc17a8 pages 13-14)
Suggested annotations are:
Preserved otoacoustic emissions and synaptic/auditory-neuropathy physiology are strongly demonstrated in mice, but should not automatically be entered as universal human phenotypes. In the null model, robust OAEs coexisted with absent sound-evoked auditory-nerve responses, localizing dysfunction downstream of outer-hair-cell amplification. (ruel2008impairmentofslc17a8 pages 1-2)
No consistent vestibular, visual, neurologic, renal, endocrine, craniofacial, or behavioral abnormality has been reported; a Korean pedigree specifically had no accompanying symptoms. (ryu2017identificationofa pages 1-6)
Disease-specific EQ-5D, SF-36, PROMIS, speech-recognition, educational, or employment data are unavailable. By clinical inference, progressive high-frequency loss can impair speech understanding—particularly consonants and speech in noise—communication, education, work, and social participation. These generic consequences should not be represented as measured DFNA25 outcomes.
SLC17A8 encodes a 589-amino-acid, predicted 12-transmembrane-domain major-facilitator-superfamily transporter. In cochlear IHCs, VGLUT3 packages glutamate into vesicles for release at ribbon synapses. (ryu2016screeningofthe pages 1-2)
Relevant molecular annotations include:
No large recurrent deletion, inversion, translocation, aneuploidy, DNA-methylation signature, or disease-specific chromatin abnormality is established. Likewise, no validated prognostic transcriptomic, circulating, metabolomic, lipidomic, or epigenomic biomarker exists.
DFNA25 is not infectious, toxic, occupational, or lifestyle-caused. Environmental exposures may add independent cochlear injury to the inherited defect. Avoidable generic hazards include excessive sound, aminoglycosides when alternatives exist, cisplatin, and other recognized ototoxins. There is no evidence that smoking, alcohol, diet, exercise, radiation, pollution, or a pathogen specifically changes SLC17A8 penetrance.
A rat salicylate model found increased IHC VGLUT3 expression and tinnitus without a significant hearing-threshold difference, but this is acquired-toxicity evidence and does not establish salicylate as a DFNA25 modifier.
The principal upstream lesion is vesicular transporter dysfunction; mechano-transduction and ribbon abnormalities may be allele-specific parallel or downstream processes. Secondary neural/circuit degeneration is downstream. No primary immune, fibrotic, ischemic, endocrine, or metabolic mechanism has been demonstrated.
Suggested cell terms are inner hair cell, type I spiral-ganglion neuron, and secondarily lateral olivocochlear efferent neuron. Suggested anatomical terms are cochlea, organ of Corti, spiral ganglion, and IHC ribbon synapse. Exact CL/UBERON identifiers should be ontology-validated during curation.
A 2024 study used subcellular fractionation, anti-VGluT3 immunoisolation, label-free LC–MS, and imaging to generate the first broad proteomic inventory of native IHC trafficking organelles. It identified an age-dependent, mixed synaptic-vesicle/endosomal signature and enrichment after hearing onset of VAMP7, syntaxins 7/8/12–13, SCAMP1, V-ATPase, SV2, and PKCα. This profiles normal VGLUT3-positive organelles rather than DFNA25 patient tissue, but supplies an authoritative molecular framework for studying variant effects. Publication: February 2024; DOI 10.1016/j.mcpro.2023.100704. (cepeda2024proteomicanalysisreveals pages 1-3)
No DFNA25 patient-derived single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, organoid, iPSC, or CRISPR-screen dataset was identified.
VGLUT3 is also expressed in selected central neurons, but DFNA25 is clinically nonsyndromic and no reproducible central-neurologic phenotype is established.
The human course is chronic and lifelong: high-frequency thresholds typically deteriorate progressively, with age-dependent clinical penetrance. There are no validated early/intermediate/end-stage definitions, median onset age, dB/year trajectory, spontaneous remissions, or episodic pattern. (ruel2008impairmentofslc17a8 pages 13-14)
The mouse evidence suggests two potentially important intervention windows. First, restoring neurotransmission before secondary spiral-ganglion loss should be advantageous. Second, treatment remains possible after auditory maturation: adult-mouse rescue has been reported, although delivery and neural preservation become more difficult. Neonatal mice are unusually permissive to AAV and do not directly model the fully developed human neonatal cochlea. (duhon2024genetherapyadvancements pages 11-12, duhon2024genetherapyadvancements pages 4-5)
Inheritance is autosomal dominant. Both sexes are expected to be affected equally and male-to-male transmission is possible. Penetrance appears age-dependent; no defensible percentage is available. Expressivity is variable, while anticipation has not been shown. Consanguinity is not etiologically important for this dominant condition.
A distant founder relationship was suggested for the two p.A211V families of Czech/German ancestry, but there is no population-wide founder-frequency estimate. Korean frameshift and splice variants demonstrate that DFNA25 is not confined to European ancestry. (ruel2008impairmentofslc17a8 pages 1-2, ryu2017identificationofa pages 1-6)
Disease-specific prevalence, incidence, carrier frequency, geographic distribution, sex ratio, and age distribution are unknown. The Korean screening study found one proposed frameshift allele among 87 unrelated ADNSHL probands, but this selected sample cannot be converted into population prevalence. For context only, the paper reported that roughly 70% of hereditary SNHL is nonsyndromic and that 10–20% of nonsyndromic cases follow dominant inheritance; these are not DFNA25-specific statistics. (ryu2016screeningofthe pages 1-2)
Recommended assessment includes otologic examination, family history over at least three generations, pure-tone air/bone audiometry, speech audiometry including speech-in-noise where available, tympanometry, and serial threshold monitoring. OAEs and ABR can help localize cochlear amplification versus IHC-synaptic/neural transmission, but no DFNA25-specific diagnostic cut-off exists.
Imaging is usually unnecessary in a classic bilateral hereditary presentation but may be appropriate for asymmetry, vestibular symptoms, cochlear-implant planning, or another suspected structural cause. Routine blood chemistry, biopsy, EEG, EMG, or metabolic testing does not diagnose DFNA25.
CMA, karyotyping, FISH, mitochondrial sequencing, and repeat-expansion testing are not first-line tests for isolated, sequence-variant-mediated DFNA25 unless another diagnosis is suspected.
The differential includes other progressive dominant nonsyndromic hearing losses—such as KCNQ4/DFNA2A, TECTA/DFNA8/12, WFS1/DFNA6/14/38, ACTG1/DFNA20/26, POU4F3/DFNA15, TMC1/DFNA36, and COCH/DFNA9—plus age/noise-related loss, ototoxicity, congenital infection, and structural disease. Vestibular dysfunction strongly suggests alternatives such as COCH-related disease. Molecular diagnosis is essential because audiograms overlap.
Newborn hearing screening can miss delayed-onset DFNA25. Children carrying a familial variant require scheduled audiologic surveillance even after a normal newborn screen.
DFNA25 is not known to reduce survival or life expectancy, and no disease-specific mortality is reported. Morbidity is auditory: progressive communication disability may eventually require amplification or implantation. Spontaneous biological recovery is not expected, although functional rehabilitation is often substantial.
Baseline severity, age of onset, serial threshold slope, speech recognition, and preservation of spiral-ganglion function are clinically relevant prognostic features. No molecular biomarker predicts progression beyond the familial variant and family-specific natural history. No five- or ten-year survival statistic is applicable.
There is no approved DFNA25-specific drug, RNA therapy, gene therapy, or pharmacogenomic guideline. Current management is individualized:
Cochlear implantation is mechanistically plausible because electrically evoked ABRs remained present in Slc17a8-null mice even when acoustic responses were absent, indicating that electrical stimulation can bypass the defective IHC synapse. This is translational inference, not a DFNA25-specific clinical outcome series. (ruel2008impairmentofslc17a8 pages 13-14)
In 2012, cochlear AAV1-VGLUT3 delivery to knockout mice produced IHC-selective protein expression and normalized ABR thresholds within two weeks. At postnatal days 1–3, round-window delivery rescued normal ABR thresholds in 19/19 mice; five followed for nine months retained normal thresholds. A 1-µL dose at 2.3×10¹³ vg/mL labeled 100% of IHCs, whereas 0.6 µL labeled about 40%; even partial IHC transduction could restore near-normal thresholds. Some rescued animals retained normal thresholds for up to 1.5 years, although neural counts and response amplitudes did not fully normalize. Publication: 26 July 2012, Neuron; DOI 10.1016/j.neuron.2012.05.019, PMID 22794260. (akil2012restorationofhearing pages 1-2, akil2012restorationofhearing pages 6-8, akil2012restorationofhearing pages 9-10)
A 2023 study summarized in a 2024 review delivered AAV-PHP.B-CBA-VGLUT3-WPRE into the cisterna magna of mice aged P28–P105. A dose of 2.27×10¹¹ vg reportedly restored hearing across tested frequencies except 40 kHz. Minimal brain expression and no liver expression were reported, but spinal-cord, dorsal-root-ganglion, and liver-vector-genome analyses were incomplete. The review appropriately highlights dorsal-root-ganglion toxicity seen in 83% of 213 nonhuman primates across other intracisternal AAV studies, making safety and species-specific tropism major translational barriers. (duhon2024genetherapyadvancements pages 11-12)
For dominant p.A211V-like disease, simple addition of wild-type SLC17A8 may not suppress a dominant-negative/toxic mutant allele. Mutation-agnostic silencing plus replacement, allele-specific silencing, or editing may ultimately be required; none has yet been validated clinically for DFNA25.
Recent expert reviews conclude that VGLUT3 replacement is among the most successful preclinical hearing-loss programs, sometimes restoring wild-type ABR thresholds, but emphasize poorer adult transduction and incomplete ABR wave-I/neural rescue. One review contrasts approximately 100% IHC/~75% spiral-ganglion-neuron transduction in neonatal mice with 100% IHC but <20% SGN transduction in adults. (duhon2024genetherapyadvancements pages 4-5)
A search of ClinicalTrials.gov found no SLC17A8/DFNA25-specific human interventional trial. Human hereditary-deafness gene-therapy trials described in the 2024 literature concern chiefly OTOF/DFNB9, not DFNA25. (zhang2024aav‐mediatedgenetherapy pages 3-4)
Primary prevention of a de novo or inherited pathogenic allele is not possible through lifestyle change. Reproductive options after molecular diagnosis include genetic counseling, natural conception with or without prenatal diagnosis, donor gametes, adoption, and IVF with preimplantation genetic testing.
Secondary prevention comprises cascade testing and longitudinal audiology, particularly because phenotype-based screening may miss young, age-dependent carriers. Early amplification and educational intervention can reduce developmental and communication consequences.
Tertiary prevention includes hearing conservation, avoidance of unnecessary ototoxic exposure, optimized amplification, vaccination and infection prevention according to routine standards—especially before cochlear implantation—and maintenance of social/communication access. These measures prevent additive injury or complications; they do not correct SLC17A8.
Orthologous Slc17a8 is conserved across vertebrates, and the p.A211 residue is conserved across species. Suggested taxa include Mus musculus (NCBI Taxonomy 10090), Rattus norvegicus (10116), Danio rerio (7955), and Homo sapiens (9606). (ruel2008impairmentofslc17a8 pages 1-2)
No well-validated, naturally occurring companion-animal or livestock counterpart attributable to an orthologous dominant SLC17A8 allele was identified; therefore no defensible VBO breed annotation or veterinary prevalence can be assigned. DFNA25 is noninfectious and has no zoonotic or cross-species transmission potential.
Targeted exon-2 deletion produces congenital profound deafness with absent acoustic auditory-nerve responses, preserved electrically evoked ABRs, and robust OAEs. Ca²⁺-triggered vesicle turnover remains intact at approximately two weeks, demonstrating that vesicle fusion can occur without glutamate loading. Afferent synapses, spiral-ganglion neurons, and lateral efferent terminals decline later. This model is excellent for transporter loss and gene-replacement studies but does not reproduce heterozygous, delayed-onset human p.A211V disease. (ruel2008impairmentofslc17a8 pages 12-13, ruel2008impairmentofslc17a8 pages 1-2)
Mouse p.A224V models human p.A211V. Homozygous knock-in mice exhibit progressive ABR loss with preserved cochlear amplification, reduced summating potentials, IHC—but not OHC—stereociliary-bundle collapse, oversized ribbons, and increased sustained-pool exocytosis. The authors concluded that DFNA25 “stems from a failure in the mechano-transduction followed by a change in synaptic transfer.” Publication: December 2021; DOI 10.1113/JP282181. The homozygous design may exaggerate a heterozygous human phenotype. (joshi2021vglut3‐p.a211vvariantfuses pages 1-2)
VGLUT3-positive IHC organelle immunoisolation and cochlear explants support biochemical and cellular studies; zebrafish offer conserved hair-cell biology and regeneration but differ from mammalian cochlear frequency tuning and OHC specialization. No validated DFNA25 patient iPSC-derived IHC or cochlear-organoid model was identified.
The causal gene–disease relationship is strong: linkage and segregation in human families align with highly specific knockout and knock-in physiology. Nevertheless, the clinical evidence base is small and family-biased. Major missing items are disease-specific prevalence, quantitative penetrance, variant-level natural history, prospective speech and quality-of-life outcomes, human cochlear-implant outcomes, validated environmental modifiers, patient-derived omics, and clinical therapeutic trials. The most important translational distinction is that successful replacement in a recessive/null mouse does not prove efficacy against a dominant human missense allele.
References
(ruel2008impairmentofslc17a8 pages 1-2): Jérôme Ruel, Sarah Emery, Régis Nouvian, Tiphaine Bersot, Bénédicte Amilhon, Jana M. Van Rybroek, Guy Rebillard, Marc Lenoir, Michel Eybalin, Benjamin Delprat, Theru A. Sivakumaran, Bruno Giros, Salah El Mestikawy, Tobias Moser, Richard J.H. Smith, Marci M. Lesperance, and Jean-Luc Puel. Impairment of slc17a8 encoding vesicular glutamate transporter-3, vglut3, underlies nonsyndromic deafness dfna25 and inner hair cell dysfunction in null mice. American journal of human genetics, 83 2:278-92, Aug 2008. URL: https://doi.org/10.1016/j.ajhg.2008.07.008, doi:10.1016/j.ajhg.2008.07.008. This article has 345 citations and is from a highest quality peer-reviewed journal.
(ryu2016screeningofthe pages 1-2): Nari Ryu, Borum Sagong, Hong-Joon Park, Min-A Kim, Kyu-Yup Lee, Jae Young Choi, and Un-Kyung Kim. Screening of the slc17a8 gene as a causative factor for autosomal dominant non-syndromic hearing loss in koreans. BMC Medical Genetics, Jan 2016. URL: https://doi.org/10.1186/s12881-016-0269-3, doi:10.1186/s12881-016-0269-3. This article has 26 citations and is from a peer-reviewed journal.
(ryu2017identificationofa pages 1-6): Nari Ryu, Seokwon Lee, Hong-Joon Park, Byeonghyeon Lee, Tae-Jun Kwon, Jinwoong Bok, Chan Ik Park, Kyu-Yup Lee, Jeong-In Baek, and Un-Kyung Kim. Identification of a novel splicing mutation within slc17a8 in a korean family with hearing loss by whole-exome sequencing. Gene, 627:233-238, Sep 2017. URL: https://doi.org/10.1016/j.gene.2017.06.040, doi:10.1016/j.gene.2017.06.040. This article has 16 citations and is from a peer-reviewed journal.
(ruel2008impairmentofslc17a8 pages 13-14): Jérôme Ruel, Sarah Emery, Régis Nouvian, Tiphaine Bersot, Bénédicte Amilhon, Jana M. Van Rybroek, Guy Rebillard, Marc Lenoir, Michel Eybalin, Benjamin Delprat, Theru A. Sivakumaran, Bruno Giros, Salah El Mestikawy, Tobias Moser, Richard J.H. Smith, Marci M. Lesperance, and Jean-Luc Puel. Impairment of slc17a8 encoding vesicular glutamate transporter-3, vglut3, underlies nonsyndromic deafness dfna25 and inner hair cell dysfunction in null mice. American journal of human genetics, 83 2:278-92, Aug 2008. URL: https://doi.org/10.1016/j.ajhg.2008.07.008, doi:10.1016/j.ajhg.2008.07.008. This article has 345 citations and is from a highest quality peer-reviewed journal.
(cepeda2024proteomicanalysisreveals pages 1-3): Andreia P. Cepeda, Momchil Ninov, Jakob Neef, Iwan Parfentev, Kathrin Kusch, Ellen Reisinger, Reinhard Jahn, Tobias Moser, and Henning Urlaub. Proteomic analysis reveals the composition of glutamatergic organelles of auditory inner hair cells. Feb 2024. URL: https://doi.org/10.1016/j.mcpro.2023.100704, doi:10.1016/j.mcpro.2023.100704. This article has 12 citations and is from a domain leading peer-reviewed journal.
(joshi2021vglut3‐p.a211vvariantfuses pages 1-2): Yuvraj Joshi, Chloé P. Petit, Stéphanie Miot, Marie Guillet, Gaston Sendin, Jérôme Bourien, Jing Wang, Rémy Pujol, Salah El Mestikawy, Jean‐Luc Puel, and Régis Nouvian. Vglut3‐p.a211v variant fuses stereocilia bundles and elongates synaptic ribbons. Dec 2021. URL: https://doi.org/10.1113/jp282181, doi:10.1113/jp282181. This article has 12 citations.
(duhon2024genetherapyadvancements pages 4-5): Bailey H. Duhon, Eric C. Bielefeld, Yin Ren, and Jerusha Naidoo. Gene therapy advancements for the treatment of acquired and hereditary hearing loss. Frontiers in Audiology and Otology, Jul 2024. URL: https://doi.org/10.3389/fauot.2024.1423853, doi:10.3389/fauot.2024.1423853. This article has 9 citations.
(zhang2024aav‐mediatedgenetherapy pages 3-4): Liyan Zhang, Fangzhi Tan, Jieyu Qi, Yicheng Lu, Xiaohan Wang, Xuehan Yang, Xiangyan Chen, Xinru Zhang, Jinyi Fan, Yinyi Zhou, Li Peng, Nianci Li, Lei Xu, Shiming Yang, and Renjie Chai. Aav‐mediated gene therapy for hereditary deafness: progress and perspectives. Advanced Science, Nov 2024. URL: https://doi.org/10.1002/advs.202402166, doi:10.1002/advs.202402166. This article has 41 citations and is from a peer-reviewed journal.
(akil2012restorationofhearing pages 1-2): Omar Akil, Rebecca P. Seal, Kevin Burke, Chuansong Wang, Aurash Alemi, Matthew During, Robert H. Edwards, and Lawrence R. Lustig. Restoration of hearing in the vglut3 knockout mouse using virally mediated gene therapy. Neuron, 75:283-293, Jul 2012. URL: https://doi.org/10.1016/j.neuron.2012.05.019, doi:10.1016/j.neuron.2012.05.019. This article has 480 citations and is from a highest quality peer-reviewed journal.
(akil2012restorationofhearing pages 6-8): Omar Akil, Rebecca P. Seal, Kevin Burke, Chuansong Wang, Aurash Alemi, Matthew During, Robert H. Edwards, and Lawrence R. Lustig. Restoration of hearing in the vglut3 knockout mouse using virally mediated gene therapy. Neuron, 75:283-293, Jul 2012. URL: https://doi.org/10.1016/j.neuron.2012.05.019, doi:10.1016/j.neuron.2012.05.019. This article has 480 citations and is from a highest quality peer-reviewed journal.
(duhon2024genetherapyadvancements pages 11-12): Bailey H. Duhon, Eric C. Bielefeld, Yin Ren, and Jerusha Naidoo. Gene therapy advancements for the treatment of acquired and hereditary hearing loss. Frontiers in Audiology and Otology, Jul 2024. URL: https://doi.org/10.3389/fauot.2024.1423853, doi:10.3389/fauot.2024.1423853. This article has 9 citations.
(bottom2024defectsinhair pages 1-2): Riley T. Bottom, Yijun Xu, Caroline Siebald, Jinsei Jung, and Ulrich Müller. Defects in hair cells disrupt the development of auditory peripheral circuitry. Nature Communications, Dec 2024. URL: https://doi.org/10.1038/s41467-024-55275-x, doi:10.1038/s41467-024-55275-x. This article has 7 citations and is from a highest quality peer-reviewed journal.
(ryu2017identificationofa pages 23-25): Nari Ryu, Seokwon Lee, Hong-Joon Park, Byeonghyeon Lee, Tae-Jun Kwon, Jinwoong Bok, Chan Ik Park, Kyu-Yup Lee, Jeong-In Baek, and Un-Kyung Kim. Identification of a novel splicing mutation within slc17a8 in a korean family with hearing loss by whole-exome sequencing. Gene, 627:233-238, Sep 2017. URL: https://doi.org/10.1016/j.gene.2017.06.040, doi:10.1016/j.gene.2017.06.040. This article has 16 citations and is from a peer-reviewed journal.
(ruel2008impairmentofslc17a8 pages 12-13): Jérôme Ruel, Sarah Emery, Régis Nouvian, Tiphaine Bersot, Bénédicte Amilhon, Jana M. Van Rybroek, Guy Rebillard, Marc Lenoir, Michel Eybalin, Benjamin Delprat, Theru A. Sivakumaran, Bruno Giros, Salah El Mestikawy, Tobias Moser, Richard J.H. Smith, Marci M. Lesperance, and Jean-Luc Puel. Impairment of slc17a8 encoding vesicular glutamate transporter-3, vglut3, underlies nonsyndromic deafness dfna25 and inner hair cell dysfunction in null mice. American journal of human genetics, 83 2:278-92, Aug 2008. URL: https://doi.org/10.1016/j.ajhg.2008.07.008, doi:10.1016/j.ajhg.2008.07.008. This article has 345 citations and is from a highest quality peer-reviewed journal.
(akil2012restorationofhearing pages 9-10): Omar Akil, Rebecca P. Seal, Kevin Burke, Chuansong Wang, Aurash Alemi, Matthew During, Robert H. Edwards, and Lawrence R. Lustig. Restoration of hearing in the vglut3 knockout mouse using virally mediated gene therapy. Neuron, 75:283-293, Jul 2012. URL: https://doi.org/10.1016/j.neuron.2012.05.019, doi:10.1016/j.neuron.2012.05.019. This article has 480 citations and is from a highest quality peer-reviewed journal.
Checked with linkml-reference-validator 0.2.1.
| Outcome | Count |
|---|---|
| References checked | 12 |
| Resolved | 12 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 12 |
| On topic | 5 |
| Off topic | 1 |
These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:
PMID:22794260 (1 mention) - Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons.Weighed against this report's own most characteristic terms: disease, human, dfna25, clinical, gene, loss, hearing, genetic, model, variant, slc17a8, dominant, cochlear, molecular, phenotype, allele, type, nonsyndromic, progressive, ihc.
All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.
Checked with linkml-term-validator 0.4.5, through the ols: adapter.
| Outcome | Count |
|---|---|
| Terms checked | 8 |
| Resolved | 8 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 0 |
| Terms whose name was checked | 1 |
| Terms named correctly | 0 |
| Terms named as a different term | 1 |
These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:
MONDO:0011568 (3 mentions) - the report calls it "if available"; MONDO calls it autosomal dominant nonsyndromic hearing loss 25